US20180057856A1 - Selective ultrasonic lysis of blood and other biological fluids and tissues - Google Patents
Selective ultrasonic lysis of blood and other biological fluids and tissues Download PDFInfo
- Publication number
- US20180057856A1 US20180057856A1 US15/666,042 US201715666042A US2018057856A1 US 20180057856 A1 US20180057856 A1 US 20180057856A1 US 201715666042 A US201715666042 A US 201715666042A US 2018057856 A1 US2018057856 A1 US 2018057856A1
- Authority
- US
- United States
- Prior art keywords
- lysis solution
- lysis
- sample
- solution
- covaris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000009089 cytolysis Effects 0.000 title claims abstract description 141
- 210000004369 blood Anatomy 0.000 title claims description 64
- 239000008280 blood Substances 0.000 title claims description 64
- 239000013060 biological fluid Substances 0.000 title description 3
- 108091005804 Peptidases Proteins 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 76
- 102000035195 Peptidases Human genes 0.000 claims abstract description 50
- 235000019833 protease Nutrition 0.000 claims abstract description 50
- 229930182490 saponin Natural products 0.000 claims abstract description 47
- 150000007949 saponins Chemical class 0.000 claims abstract description 47
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 45
- 239000012472 biological sample Substances 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000002604 ultrasonography Methods 0.000 claims abstract description 19
- 230000002934 lysing effect Effects 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 135
- 239000000523 sample Substances 0.000 claims description 102
- 210000004027 cell Anatomy 0.000 claims description 65
- 244000005700 microbiome Species 0.000 claims description 59
- 239000004365 Protease Substances 0.000 claims description 33
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 33
- 235000019419 proteases Nutrition 0.000 claims description 33
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 32
- 239000003599 detergent Substances 0.000 claims description 29
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 28
- 241000894006 Bacteria Species 0.000 claims description 24
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 22
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 22
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 22
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 20
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 17
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 241000981399 Aspergillus melleus Species 0.000 claims description 10
- 229920004890 Triton X-100 Polymers 0.000 claims description 10
- 239000013504 Triton X-100 Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 241001092473 Quillaja Species 0.000 claims description 5
- 235000009001 Quillaja saponaria Nutrition 0.000 claims description 5
- 210000003097 mucus Anatomy 0.000 claims description 5
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000003196 chaotropic effect Effects 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 102000000019 Sterol Esterase Human genes 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 2
- 235000017709 saponins Nutrition 0.000 description 41
- 238000001514 detection method Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 18
- 238000009640 blood culture Methods 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 16
- 238000004949 mass spectrometry Methods 0.000 description 16
- 238000012545 processing Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000004695 Polyether sulfone Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229920006393 polyether sulfone Polymers 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229920002113 octoxynol Polymers 0.000 description 7
- 238000003260 vortexing Methods 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000006150 trypticase soy agar Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000012465 retentate Substances 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108020004418 ribosomal RNA Proteins 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 241000894007 species Species 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 241000607715 Serratia marcescens Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000014670 detection of bacterium Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000004878 Gelsolin Human genes 0.000 description 2
- 108090001064 Gelsolin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 208000037815 bloodstream infection Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000013541 low molecular weight contaminant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940052223 basic fuchsin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000003234 fluorescent labeling method Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- -1 polytetrafluorethylene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Definitions
- This invention pertains to the field of detection, identification and characterization of microorganisms in complex, cell-containing biological fluids and tissues.
- the ability to detect and characterize low levels of microorganisms in biological samples is valuable for many applications including diagnosing and treating infections in both humans and animals, infectious disease research, detecting food contamination and identifying the causative organisms, monitoring product quality during food processing, monitoring environmental quality and so on.
- Culture is often used to facilitate the detection and characterization of microorganisms in biological samples.
- the samples are incubated in an atmosphere and at a temperature that is conducive to the growth of microorganisms, possibly with the addition of nutrient media to sample. Under these conditions, the microorganisms will multiply and can reach high concentrations.
- a variety of methods can be used for the detection and characterization of the microorganisms. These methods include staining, fluorescence-in-situ-hybridization (FISH), polymerase-chain-reaction (PCR) and matrix-assisted-laser-desorption-ionization (MALDI) mass spectrometry.
- FISH fluorescence-in-situ-hybridization
- PCR polymerase-chain-reaction
- MALDI matrix-assisted-laser-desorption-ionization
- a range of bioanalytical methods rely on the lysis of cells for the release of intracellular components.
- Such components include organelles such as mitochondria, lysosomes, and endoplasmic reticulum, molecular assemblies such as microtubules and ribosomes and molecules such as proteins, carbohydrates and nucleic acids.
- the intracellular components can be subjected to analysis by for example electrophoresis, chromatography, mass spectrometry or optical spectroscopy.
- molecular methods such as PCR, microarray analysis and sequencing rely on cell lysis for the release of intracellular DNA and RNA for amplification and other kinds of processing.
- various cell lysis methods have been developed. Such methods include osmotic, chemical, mechanical (e.g. grinding with beads), hydrodynamic (e.g. pressure cell) and acoustic (i.e. sonication with ultrasound).
- Ultrasound (acoustic waves beyond the audible range) has been used to lyse cells to release contents for molecular analysis often in conjunction with beads. See Seiter, J. A. and Jay, J. M. 1980 5 .
- U.S. Pat. No. 5,374,522 (Murphy et al.) describes the use of an ultrasonic bath to disrupt cells such as Mycobacterium tuberculosis in a sample to which beads of glass or other materials in the range of 50 microns to 1 mm have been added. Such disruption released RNA and DNA into solution for hybridization with genetic probes.
- Taylor et al. teach a method for disrupting cells or viruses in a chamber with an ultrasonic transducer.
- 7,541,166 describe an apparatus that allows a sample or parts of a sample to be moved into a sonication chamber multiple times, allowing differing sonication levels to be applied to more and less sensitive cells such as epithelial and sperm cells releasing their DNA for analysis at different times.
- red blood cells lyse fairly readily compared to the white blood cells and selective red blood cell lysis can be accomplished simply with osmotic shock.
- Agents that selectively lyse bacteria but not mammalian cells have potential utility in combating infections.
- Selective lysis can be useful for biological research. Grifantini and coworkers were able to isolate adherent bacteria co-cultured with epithelial cells for gene expression studies by selectively lysing the epithelial cells with saponin. 4
- Direct assays for the detection of microorganisms in biological fluids are often hampered by the presence of endogenous cells in high numbers.
- such assays can be simplified if a method for selectively removing the endogenous cells were available.
- Zierdt and his colleagues published a lysis method in 1977 1 . This method uses a mild detergent solution containing an enzyme mixture (Rhozyme prepared from Aspergillus oryzae cultures).
- Zierdt refined the solution by substituting the less toxic detergent Tween 20 for the Triton X-100 used in the original protocol.
- the Zierdt method is able to process a suitable volume of blood, 1 mL for example, in 1 hour, yielding a clear, red solution that can be filtered through a 0.6 micron track-etch filter 8 mm in diameter in approximately 3 minutes using a pressure differential of 2.5 psi.
- a key advantage of the Zierdt method is that the product is filterable through filters with pores small enough to retain microorganisms. Following filtration, the filter can be placed on a nutrient plate under suitable conditions, allowing colonies to grow from individual cells. The colonies can then be counted and further analyzed for the identity and antibiotic susceptibility of the organisms.
- FISH or other fluorescent labeling methods can be applied to the cells and fluorescence microscopy used to directly visualize the cells on the filter.
- fluorescence microscopy used to directly visualize the cells on the filter.
- NALC N-acetyl-L-cysteine
- the present invention is directed to achieving the objectives above by means of the surprising discovery that endogenous mammalian cells in a biological sample can be rapidly and effectively lysed while leaving the cells of any microorganisms that may be present substantially intact by mixing the sample with a lysis solution as described herein and subjecting the mixed sample to high-frequency ultrasound of prescribed frequency, power, duty cycle and duration.
- the invention is also directed to liquefying highly viscous biological samples in a rapid manner while preserving substantially all the microorganisms present in viable form, by mixing the sample with an appropriate lysis solution as described herein and subjecting the sample to high-frequency ultrasound of prescribed frequency, power, duty cycle and duration.
- This invention also provides a method for rapidly and effectively capturing microorganisms in intact and viable form from highly cellular and/or viscous biological samples by mixing the sample with an appropriate lysis solution as described herein and subjecting the sample to high-frequency ultrasound of prescribed frequency, power, duty cycle and duration and filtering the treated sample through a filter.
- FIG. 1 is a graph that shows the filterability of whole blood: lysis solution with and without ultrasonic treatment.
- FIG. 2 shows the results of Fluorescence in situ Hybridization (FISH) experiments for Coagulase Negative Staphylococcus (CNS).
- FISH Fluorescence in situ Hybridization
- FIG. 3 is a graph that shows peptide nucleic acid (PNA) FISH detection of bacteria in platelet concentrates by CFU/mL.
- PNA peptide nucleic acid
- FIG. 4 shows the results of FISH experiments for the detection of Bacillus cereus in concentrated platelets.
- FIG. 5 are two panels that show the results of FISH experiments for the detection of Staphylococcus aureus (top) and Serratia inarcescens (bottom) in clinical bronchoalveolar lavage.
- Described by the present invention are methods for selective lysis of endogenous cells in a biological sample and method for detecting, identifying, characterizing or quantifying microorganisms in a biological sample, where the sample comprises a mixture of endogenous cells and microorganisms.
- the present inventors have found that endogenous cells in a biological sample can be rapidly and effectively lysed while leaving the cells of any microorganism that may be present in the sample substantially intact.
- endogenous cells is meant to refer to those cells that are produced by or originate from or are growing within an organism, tissue or biological sample.
- an endogenous cell may be a mammalian cell.
- a biological sample may be a body fluid, for example, but not limited to, blood or blood fractions, blood culture fluid, respiratory secretions, cerebrospinal fluid, urine, stool, wound exudates and naso-pharyngeal fluid or mucus.
- the biological sample may be platelets, platelet concentrate or a mammalian cell culture.
- the biological sample may be food or edible products.
- the phrase “substantially intact” is meant to mean that the microorganisms are viable (i.e. they are capable of growing) or that their cells appear to be intact when imaged under a microscope in either stained or unstained form.
- the phrase “substantially intact” is meant to refer to at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more of the microorganisms in the sample are recovered.
- the method comprises mixing the biological sample with a lysis solution, and subjecting the mixture to ultrasound at a controlled temperature, thereby selectively lysing the endogenous cells in the biological sample.
- the Zierdt method has the drawbacks of a lengthy incubation, a large (10:1) dilution of the sample, and the presence of residual blood cell nuclei in the lysed sample.
- Lysis solutions can be useful in assays for microorganisms for the purpose of lysing endogenous cells as well as liquefying and clarifying mucus and phlegm containing samples.
- various compositions of lysis solutions have been developed often containing detergents, enzymes, salts and buffering agents.
- Saponins produced by certain plants, are ambipathic glycoside detergent compounds that bind cholesterol. Saponins have been found to be particularly effective for the selective lysis of mammalian cells in microbial cell assays.
- the Dorn method requires mixing the blood with the saponin-containing lysis solution followed by 30 minutes of centrifugation. After centrifugation, the majority of the supernatant is removed and discarded. The microorganism-containing pellet is resuspended and distributed onto growth media for culture. After culture, colonies can be counted and analyzed. While quantitative, this method requires overnight culture and is somewhat labor intensive.
- Richards teaches the use of saponin to lyse blood containing phagocytosed pathogens to release degraded pathogen while leaving unphagocytosed pathogens intact. Antigens from the degraded pathogens are detected with an immunoassay while the intact pathogens arc cultured for confirmation of the assay result. Richards extends the Dorn method and allows detection of certain microbial antigens in one hour. The antigens are cell membrane constituents (lipoteichoic acid and peptidoglycan) which are not very specific. The ability of this method to identify microorganisms is therefore limited.
- lysis solutions can comprise detergents or detergents combined with proteinase.
- the lysis solution comprises a detergent and a proteinase.
- Detergents useful in the invention include, but are not limited to, saponin, nonionic surfactants such as Triton X-100 and polysorbate surfactants such as Tween 20.
- detergent concentrations can range from 0.1 to 10%.
- Proteinases useful in the invention include proteinases derived from Aspergillus (e.g. Aspergillus melleus ) which have broad enzyme activity and those with more specific activity like Streptokinase which speeds the dissolution of fibrin clots.
- Proteinase from Aspergillus melleus in the range of 8 Units/mL to 160 Units/mL has been shown to work.
- Other enzymes can be combined with proteinase to promote the breakdown of certain biomolecules.
- Cholesterol esterase, lipase and DNase are examples of enzymes that can be used in combination with proteinase.
- Reducing agents such as TCEP can be helpful for liquefying mucoid samples by reducing the disulfide bonds in mucin strands.
- Chaotropic agents such as guanidinium chloride can also aid in the dissolution of mucin gels by disrupting non-covalent bonds. Hypotonic salt solutions can also promote lysis.
- the present inventors have found that a combination of saponin with proteinase from Aspergillus melleus in a phosphate buffer is particularly effective.
- the present invention features a lysis solution comprising a detergent and a proteinase, preferably a lysis solution comprising Saponin and Proteinase.
- the lysis solution further comprises a Sodium Phosphate buffer, pH 8.
- the lysis solution preferably comprises 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%, 1.16%, 1.17%, 1.18%, 1.19%, 1.2%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%, 1.29%, 1.30%, 1.31,%, 1.32%, 1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.40%, 1.41%, 1.42%, 1.43%,1.44%, 1.45%, 1.46%, 1.47%, 1.48%, 1.49%, 1.50%, 1.55%, 1.60%, 1.65%, 1.70%, 1.72%, 1.75%, 1.80%, 1.82%, 1.85%, 1.90%, 1.92%, 1.95%, 2.0%, 2.2%, 2.5%, 3.0%, 3.1%
- the lysis solution preferably comprises 5.0, 5.25, 5.5, 6.0, 6.25, 6.5, 7.0, 7.25, 7.5, 8.0, 8.25, 8.5, 9.0, 9.25, 9.5, 10.0, 10.25, 10.5, 11.0, 11.25, 11.5, 12.0, 12.25, 12.5, 13.0, 13.25, 13.5, 14.0, 14.25, 14.5, 15.0, 15.25, 15.5, 16.0, 16.25, 16.5, 17.0, 17.25, 17.5, 18.0, 18.25, 18.5, 19.0, 19.25, 19.5, 20.0, 20.25, 20.5, 21.0, 21.25, 21.5, 22.0, 22.25, 22.5, 23.0, 23.25, 23.5, 24.0, 24.25, 24.5, 25.0, 25.25, 25.5, 26.0, 26.25, 26.5, 27.0, 27.25, 27.5, 28.0, 28.25, 28.5, 29.0, 29.25, 29.5, 30.0, 31.25, 31.5, 32.0, 32.25, 32.5
- Buffer concentrations from 0.01M to 0.1M have been tested. Tris and DNase running buffer have been used in place of sodium phosphate buffer. Accordingly, in further related embodiments, other buffers known to one skilled in the art can be used. It is therefore likely that other buffers can be substituted.
- the lysis solution comprises
- the Saponin is from Quillaja bark.
- the Proteinase is from Aspergillus melleus.
- the lysis solution comprises
- ultrasound has been used to lyse cells to release the intracellular contents for molecular analysis. Beads of glass or other materials are often added to the sample to increase the mechanical action of the ultrasound. Transducers of various shapes have been used. In the prior work the outcome has been the comprehensive lysis of all the cells in the sample. By contrast, in the methods of the present invention the selective lysis of particular cell populations is achieved.
- Two rather different types of ultrasound generating equipment are available. They are distinguished by the operating frequency. One type operates in the frequency range of 20 kHz (just above the range of human hearing) to about 80 kHz. The other type operates in the frequency range of 500 kHz to 1.5 MHz or higher and is often called megasonics. In the former, the wavelength of the sound waves ranges from about 80 mm to about 20 mm; while in the latter, the wavelength ranges from about 3 mm to about 1 mm. The shorter wavelengths produced in the megasonic range allow better localization of the sonic energy to the biological sample that may have a volume of approximately 1 cm 3 .
- bubbles produced by cavitation will generally be smaller at higher frequencies since the shorter cycles give them less time to grow before they collapse in the compressive phase of the cycle.
- high frequency ultrasound is meant to refer to ultrasound in the megasonic range.
- Some embodiments described below employ the Covaris S2 high frequency ultrasound system.
- a concave transducer is used to focus the acoustic energy on the sample.
- the transducer operates in a water bath in which the sample tube is immersed.
- the acoustic energy is coupled to the sample by the water.
- the system operates at approximately 500 KHz in a pulsed mode. The number of cycles per burst, the duty cycle, time duration and the intensity are settable on the instrument.
- a planar transducer emits a directed beam of ultrasound.
- the diameter of the beam is governed by the size of transducer.
- the system operates at approximately 1 MHz.
- the duty cycle, time duration and the intensity are settable on the instrument.
- Sonic energy from the transducer can be coupled into the biological sample by water, a gel, or an elastomer.
- the present inventors have found that when used as described above, these systems are effective in achieving the selective lysis of mammalian cells while leaving microorganisms intact and viable.
- 0.6 micron and 0.45 micron filters are commonly used to capture bacteria and fungi from liquid samples.
- 0.45 micron and 0.2 micron filters are commonly used for filter sterilization of water and media. Blood and other cell-containing biological samples are not directly filterable with these filters because the filters are rapidly clogged by these highly cellular liquids. Filterability is a good measure of the effectiveness of a lysis procedure.
- Membrane filters made of nylon, polycarbonate, polyester and aluminum oxide have been used. Track-etch membranes of polycarbonate or polyester are useful if it is desired to image microorganisms in a sample after the lysis procedure. These membranes feature smooth, flat surfaces with well-controlled cylindrical pores. Anopore (aluminum oxide) filters are also flat with well-controlled pores and thus useful for imaging. Pore sizes from 0.2 to 1 micron are effective for retention of bacteria and yeast with 0.45 to 0.8 micron being most useful. Larger pore sizes (up to 4 microns) can be used if only yeast (fungi) are of interest.
- the first class encompasses culture-based methods whereby any microorganisms present in the biological sample are allowed to grow perhaps with the admixture of nutrient media into the sample.
- the growth of the microorganism(s) can be detected in various ways, such as by changes in the turbidity or the pH of the sample or by the evolution of CO 2 driven by the metabolic activity of the microorganisms during their growth.
- Microorganisms can be identified on the basis of which of a range of biochemical nutrient sources they are able to utilize for growth.
- the second class of assays involve the use of stains, binding agents or probes to confer a detectable color or label to the cells of any microorganisms that may be present. Microscopic examination is generally used to visualize the colored or labeled cells.
- the Gram stain is an example of a stain that is commonly used in microbiology. It involves the use of crystal violet and iodine to stain fixed bacterial cells. Gram positive bacteria can be distinguished from Gram negative bacteria by their ability to retain the purple color of the crystal violet stain after washing with alcohol or acetone. Gram negative bacteria lose the purple color during the wash and are stained pink by the counter-stain, usually safranin or basic fuchsin, applied after the wash.
- Antibodies are examples of binding agents. Antibodies that recognize and bind to bacterial cell-surface molecules have been developed. Such antibodies can be chemically modified to incorporate fluorescent tags. They can be utilized in assays such as direct fluorescence assays (DFA) in which one or more fluorescently tagged antibodies are mixed with the biological sample to be tested and incubated to allow antibody binding. Following a wash step, the sample is examined with a fluorescent microscope to detect cells to which the fluorescent antibodies have bound.
- DFA direct fluorescence assays
- Other examples of binding agents include aptamers, peptides, lectins and phages.
- Probes are molecules that incorporate nucleobases. They can bind to DNA or RNA by hydrogen bonding of the nucleobases in the probe to complementary nucleobases in the DNA or RNA in a process called base pairing. Probes can be made up of DNA, PNA (peptide nucleic acid), LNA (locked nucleic acid), and related molecules and combinations thereof. The number and sequence of the nucleobases in a probe determine what target sequence the probe will bind to according to the rules of base pairing, as well as the strength and specificity of the binding. The strength of the binding under various conditions of salt concentration and pH depends on type(s) of the component molecules (DNA, PNA, LNA and others) that make up a probe. Probes can incorporate fluorescent labels that make them detectable by fluorescence imaging.
- fluorescent labels fluorophores
- excitation and emission wavelengths ranging from the ultraviolet to the near-infrared regions of the electromagnetic spectrum. Labels further differ in the width of the excitation and emission bands, the Stokes shift, and the fluorescence lifetime.
- Representative fluorescent labels include fluorescein, tetramethyl rhodamine, Texas Red, and Cy5.
- Fluorescence-in-situ-hybridization is an assay utilizing fluorescently labeled probes.
- probes directed at ribosomal RNA rRNA
- the sequence of rRNA varies from species to species. This allows FISH assays to be made species-specific through the proper design of the probe sequence.
- Agents that help to preserve RNA directly such as TCEP and the cationic, quaternary ammonium salts, tetra- and hexa-decyltrimethylammonium bromide, like those found in RNAprotect Bacteria Reagent (Qiagen 76506) or indirectly by maintaining the bacterial cell wall (e.g.
- PNA FISH assays are commercially available for diagnostic use in hospital clinical microbiology laboratories for the identification of microorganisms in suspected blood stream infections.
- the probes comprise fluorescently labeled PNA molecules.
- the third class of assays for the detection and identification of microorganisms encompasses those that involve the use of molecular methods, including amplification techniques such as PCR.
- the target is microbial DNA, RNA or proteins that have been released by the lysis or rupture of the cells.
- the product(s) of the amplification can be detected by sequencing, through the use of microarrays, by the use of intercalating dyes or with probes carrying a detectable label such as one or more fluorophores or nanoparticles.
- Amplification-based methods suffer from certain drawbacks including false negatives due to inhibitors present in many biological samples, and false positives caused by remnant DNA from microorganisms killed by host defense mechanisms.
- Selective ultrasonic lysis of whole blood, concentrated platelets, respiratory secretions, urine, or blood culture for the purpose of microbial detection is carried out by treating the sample with a buffered solution comprised of saponin or Tween-20 and proteinase in a ratio ranging from 1:1 to 1:4; lysing the mixture with focused or planar high-frequency ultrasonic waves; and concentrating the lysed sample via filtration or centrifugation.
- Detection can then be accomplished by the following additional steps: rinsing the concentrate; probing the rinsed concentrate with fluorescently labeled PNA probes and hybridizing the probes to specific rRNA targets; stringent washing to remove unbound and non-specifically hybridized probe; and analyzing the sample to detect fluorescent microorganisms. These are the preferred protocols.
- the lysis solutions were optimized individually for each sample type. Saponin was chosen for the lysis of whole blood and platelets for its superior ability to lyse blood cell membranes while leaving bacterial cells intact. Tween-20 was used in place of saponin for respiratory secretions because the sample was easier to filter after treatment with Tween-20 while still preserving the microorganisms.
- the concentration of saponin and/or proteinase may be increased to promote filterability or decreased to improve recovery. Additional agents to promote degradation of fibrin clots and filterability such as Streptokinase may be added.
- Proteinase may be added to this formulation to increase filterability.
- Bond Breaker TCEP Solution (Thermo Scientific 77720) may be added to the preparation to protect RNA and/or to improve filterability of respiratory secretions. 2) For very thick, mucoid respiratory secretions or for blood culture with 10 5 CFU/mL or more less sample may be added to the preparation and the difference in volume may be replaced with additional lysis solution, water, or buffer. 3) Anti-coagulants other than those listed above may be used for whole blood and concentrated platelets.
- the sample was treated with acoustic energy to promote mixing, selectively lyse human cells over bacteria and yeast, and break apart sample matrix for improved filtration. This has been done with focused acoustic energy in the Covaris S2 and non-focused acoustic energy with the ProSys.
- Possible perturbations 1) Reduce treatment time in step 5 and 6 to 30 seconds and cycles/burst to 500 in step 5 and to 100 in step 6 to improve recovery in platelets. 2) Treat urine with 3 cycles of step 6 only. 3) Treat blood culture with 1 cycle of step 6 only.
- the lysate was concentrated on an aluminum and SiO 2 coated polycarbonate track etched membrane (PCTE) filter bonded to a plastic slide with a ring press and supported by a stainless steel fit.
- PCTE polycarbonate track etched membrane
- the slide was held in a custom-built, heated slide holder with a vacuum manifold.
- the filtration area was 52 mm 2 .
- the lysate may be rinsed with a 1% solution of dextran sulfate, RNAprotect, and/or 400 mM MgCl 2 in 1 ⁇ PBS to improve hybridization and detection. 2) The lysate may be concentrated using centrifugation rather than filtration. 3) Less than the entire volume of lysate may be filtered for samples from which only high colony count organisms are relevant like urine.
- the concentrated, hybridized lysate may be fixed to and viewed, imaged, and/or scanned on a solid surface rather than a filter.
- MS mass spectrometry
- the detection, identification, characterization or quantification is done by a mass spectrometer, which may be one of the following: matrix-assisted-laser-desorption-ionization (MALDI) mass spectrometry (e.g. MALDI-TOF MS), Tandem MS, ESI-TOF, ESI-iontrap, LC-MS, GC-MS, ion mobility MS, laser desorption ionization mass spectrometry (LDI-MS) and quadrupole-MS.
- MALDI matrix-assisted-laser-desorption-ionization
- Mass spectrometry is a sensitive and accurate technique for separating and identifying molecules.
- mass spectrometers have two main components, an ion source for the production of ions and a mass-selective analyzer for measuring the mass-to-charge ratio of ions, which is and converted into a measurement of mass for these ions.
- ion source for the production of ions
- mass-selective analyzer for measuring the mass-to-charge ratio of ions
- mass spectrometry methods for example, quadrupole mass spectrometry, ion trap mass spectrometry, time-of-flight mass spectrometry, gas chromatography mass spectrometry and tandem mass spectrometry, can utilize various combinations of ion sources and mass analyzers which allows for flexibility in designing customized detection protocols.
- mass spectrometers can be programmed to transmit all ions from the ion source into the mass spectrometer either sequentially or at the same time.
- a mass spectrometer can be programmed to select ions of a particular mass for transmission into the mass spectrometer while blocking other ions.
- Mass spectrometers can resolve ions with small mass differences and measure the mass of ions with a high degree of accuracy.
- the high degree of resolution and mass accuracy achieved using mass spectrometry methods allows the use of large sets of tagged probes because the resulting reporter tags can be distinguished from each other.
- the ability to use large sets of tagged probes is an advantage when designing multiplex experiments.
- Mass spectrometers achieve high sensitivity by utilizing a large portion of the ions that are formed by the ion source and efficiently transmitting these ions through the mass analyzer to the detector. Because of this high level of sensitivity, even limited amounts of sample can be measured using mass spectrometry.
- Mass spectrometry methods are well known in the art (see Burlingame et al. Anal. Chem. 70:647R-716R (1998); Kinter and Sherman, Protein Sequencing and Identification Using Tandem Mass Spectrometry Wiley-Interscience, New York (2000)).
- MALDI-TOF mass spectrometry has emerged as a powerful tool for the identification of bacteria and other microorganisms.
- the advantages of this approach include relatively straightforward sample preparation and rapid analysis. Intact bacterial cells from, for example, a colony can be mixed with MALDI matrix and applied directly to the MALDI sample plate. Pattern recognition applied to the complex spectra that are obtained allows identification of bacteria, often to the strain level (see Lay. Mass Spectrometry Reviews 20: 172-194 (2001)).
- Mass spectrometry and MALDI-TOF in particular is well suited for the analysis of microorganisms obtained using the methods of the invention.
- a lysis solution based on Zierdt's refined lysis solution which contained Rhozyme 41 (Rohm and Hass, Philadelphia, Pa.), a crude proteinase mixture extracted from Aspergillus oryzae and Tween-20 in sodium phosphate buffer. Rhozyme 41 was no longer available; proteinase from Aspergillus melleus was substituted.
- Rhozyme 41 was no longer available; proteinase from Aspergillus melleus was substituted.
- the mixtures of blood and lysis solution were subjected to one hour incubation at 37° C., focused ultrasonic waves in the Covaris, or no treatment. Then they were tested for filterability and examined microscopically to assess the number of residual cells.
- lysis solutions Two lysis solutions were made—one with and one without detergent.
- the lysis solutions were made by adding 350 ⁇ L of Tween-20 to 49.65 mL of 0.01 M sodium phosphate buffer and mixing thoroughly. Then, if required, 250 mg of proteinase were added and briefly vortexed to dissolve. Lysis solutions were filtered with a 0.2 ⁇ m, 32 mm, PES syringe filter.
- Samples were prepared by adding 0.5 mL of whole blood and 0.5 mL of lysis solution (1:1) to a 2 mL, round-bottom, snap-cap, plastic microcentrifuge tube (Eppendorf 022363352) or 0.1 mL of blood and 0.9 mL of lysis solution (1:10). The samples were capped and inverted to mix. The samples remained at these concentrations during the incubation at 37° C. or treatment with the Covaris. The 1:1 sample was diluted 1:5 before being examined microscopically or tested for filterability in order to obtain the same blood to fluid ratio as the 1:10 samples.
- Results showed that treatment with ultrasonic energy produced a lysate that was more filterable and contained less cellular debris than the Zierdt method (Table 1). Although not tested during these experiments, other work showed the Zierdt method produced a product that was not filterable if used in a 1:1 mixture with whole blood. They also demonstrated that the composition of the lysis fluid has secondary contributions to filterability. However, it was unclear whether the significant gain in filterability for the 1:1 sample with detergent and proteinase over the sample with detergent only was due to the proteinase or the warmer Covaris bath. Further experiments were conducted at the same temperature.
- Candida albicans, Candida krusei, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis were subcultured to non-selective agar media. The plates were incubated at 37° C. overnight. The following morning they were inoculated to broth media from the freshly subcultured agar media and allowed to incubate at 37° C. for 2.5 hours. Bacteria and yeast were diluted serially with 1 ⁇ PBS with 0.05% Tween-20 to 1:1,000 or 1:10,000.
- Lysis solution was made by adding 350 ⁇ L of Tween-20 to 49.65 mL of 0.01M sodium phosphate buffer and mixing thoroughly. Then 250 mg of proteinase were added and briefly vortexed to dissolve. The lysis solution was filtered with a 0.2 ⁇ m, 32 mm, PES syringe filter.
- Samples were prepared by adding 0.5 mL of whole blood, 0.5 mL of lysis solution, and 10 to 40 ⁇ L. of the diluted microorganisms to a 2 mL, round-bottom, snap-cap, plastic microcentrifuge tube. The samples were capped and inverted to mix. 100 ⁇ L of the blood mixture were plated using a plate spinner and a disposable, sterile T-spreader before and after treatment with the Covaris. The plates were incubated overnight at 37° C. overnight. Colonies were counted and recorded the following morning to determine percent yield (Table 4). This experiment was performed three times.
- Covaris S2 Samples were treated with the Covaris S2.
- the Covaris bath was filled with deionized water and degassed for 30 minutes. The water bath was maintained at 20° C.
- the Covaris samples were treated for 60 consecutive seconds at an intensity of 2, 10% duty cycle, and 200 cycles per burst.
- Staphylococcus aureus that had been diluted serially was inoculated into sterile, fresh, whole, sodium heparin treated blood and incubated to allow for phagocytosis.
- the blood was then split into two samples and subjected to either selective lysis or turned into a mock blood culture. The portion that underwent selective lysis was filtered. The filter was placed on an agar plate and incubated overnight. Colonies were counted in the morning.
- the portion that was made into a mock blood culture was incubated two days and checked for growth using Gram stain and subculture to an agar plate. The results of both methods were compared to the number of CFU initially inoculated into the blood and to each other.
- SA (ATCC 29213) was subcultured to trypticase soy agar with 5% sheep blood and incubated at 37° C. overnight. The following morning it was inoculated into trypticase soy broth and incubated at 37° C. at 180 rpm for 2 hours. The broth was then diluted serially 1:10 with 1 ⁇ phosphate buffered saline with 0.05% Tween-20 to 1 ⁇ 10 ⁇ 9 .
- the lysis solution was prepared by adding 140 mg of saponin to 10 mL of 0.1M sodium phosphate buffer, pH 8 and vortexing to dissolve. Then 51 mg of proteinase were added and vortexed briefly to dissolve. The solution was filtered with a 0.2 ⁇ L, 32 mm, PES syringe filter.
- the mock blood cultures were incubated for 2 days at 37° C. and 180 rpm. They were Gram stained and subcultured semi-quantitatively to trypticase soy agar each morning to monitor for growth. The agar subcultures were incubated overnight at 37° C. and examined for growth the following morning.
- the bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes.
- the aliquots that were mixed with lysis solution were loaded into the custom tube holder designed to fix the X and Y axis.
- the samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst.
- the lysed samples were filtered on Microfil V filtration devices that had been pre-wetted with 1 ⁇ phosphate buffered saline.
- the filters were rinsed with more 1 ⁇ phosphate buffered saline.
- the filters were removed from the device, placed on trypticase soy agar, and incubated overnight at 30° C. The filters were examined for growth the following morning, and colonies were counted.
- EDTA ethylenediaminetetraacetic acid
- CNS catheter-related blood stream infections
- 10 6 cfu/mL Coagulase Negative Staphylococcus (CNS) were received frozen. They were defrosted, mixed with lysis solution, treated with focused ultrasonic energy, and filter concentrated. The retentate was probed using the PNA Flow FISH method on the membrane and examined using fluorescent microscopy.
- Lysis solution was prepared by adding 115 mg of saponin to 10 mL of 0.1M sodium phosphate buffer, pH 8 and vortcxing to dissolve. 11.25 Units/mL of proteinase were added and vortexed briefly to dissolve. The solution was filtered using a 0.2 ⁇ m, 32 mm, PES syringe filter.
- Samples were prepared by adding 1 mL of lysis solution and 1 mL of defrosted blood to a 3 mL, round bottom, glass Covaris tube. The samples were mixed by inversion.
- the bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes.
- the tubes were loaded into the custom tube holder designed to fix the X and Y axis.
- the samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. Then the intensity was increased to 2 for 60 seconds. Finally, the cycles per burst were decreased to 200 for 60 seconds.
- the lysed samples were filter-concentrated, hybridized, washed, and mounted as described in the Preferred Embodiments section.
- the retentate was probed with a three probe mixture containing a S. aureus specific, fluorescein-labeled probe, a CNS specific, TAMRA-labeled probe, and universal bacteria, Cy5-labeled probe.
- the slide-bound membranes were examined using a fluorescent microscope, a 60 ⁇ oil objective, and the Advanllx PNA FISH filter cube (XF 53) for fluorescent organisms. CNS was detected in all 4 samples ( FIG. 2 ).
- An adjustable tube holder for the ProSys megasonic bowl was devised by attaching a clip to a manual positioning stage of the kind used for optics prototyping.
- the tool clip was kept level to keep the sample parallel to the transducer surface.
- the positioning stage allowed the height of the tube to be precisely adjusted in order to maximize the amount of activity within the sample while it was being treated with the ProSys.
- the ProSys bowl was filled with deionized water.
- the transducer was used to heat the water in the bowl until it reached 35° C.
- Lysis solution was made by adding 115 mg of saponin to 10 mL of 0.1 M sodium phosphate buffer and vortexing to dissolve. Then 112.5 units of proteinase were added and briefly vortexed to dissolve. The lysis solution was filtered with a 0.2 ⁇ m, 32 mm, PES syringe filter.
- Samples were prepared by adding 1 mL of whole blood and 1 mL of lysis solution to a 15 mL Falcon tube. The tubes were sealed with a cyclic-olefin polymer (COP), pressure-sensitive adhesive tape (Adhesives Research, ARseal 90404) and mixed by inversion.
- COP cyclic-olefin polymer
- Adhesives Research, ARseal 90404 pressure-sensitive adhesive tape
- the tubes were clipped topside down to the tube holder and lowered into the bath until fully submerged. They were treated with the ProSys for 5 consecutive minutes with 45 watts, 100 ms pulse, and 50% duty cycle. The temperature was maintained in the bowl between 36° C. and 38° C. by removing warm water and replacing it with icy, deionized water. The lysate was removed from the tube holder and tested for filterability as described in Example 1. Identical samples were subjected to focused sonic lysis by the Covaris in parallel with the ProSys samples for comparison (Table 6). This experiment was performed four times.
- Escherichia coli was subcultured to a trypticase soy agar (TSA) plate and incubated at 37° C. overnight. The following morning it was inoculated to trypticase soy broth (TSB) media from the freshly subcultured plate and allowed to incubate at 37° C. for 2 hours. 350 ⁇ L of sterile broth were added to 600 ⁇ L of broth culture. The E. coli were further diluted serially with 1 ⁇ PBS with 0.05% Tween-20 to 1:10,000. 20 ⁇ L of diluted culture were added to samples prepared as described above.
- TSA trypticase soy agar
- TSA trypticase soy agar
- TSA trypticase soy broth
- Platelets from one unit of blood (450 mL) were separated and concentrated in approximately 30 mL of plasma by centrifugation. 1 mL aliquots of platelet concentrate were inoculated with bacteria, mixed 1:1 with lysis solution, and selectively lysed using the Covaris S2. The lysates were filtered, and the retentates were probed with fluorescently labeled universal bacteria PNA probe. The filters were examined on a fluorescent microscope for the presence of bacteria. The platelets were plated pre- and post-lysis to determine the detection limits of this invention.
- the platelets were stored on a rotational shaker (Manufacturer: VWR, Model: S-500 Orbital Shaker) at ambient temperature.
- the speed of oscillation was set between 3 and 4 such that an overall speed of 70 rotations per minute was achieved. Platelets were extracted from the bag in a laminar flow hood using aseptic technique.
- Lysis solution was prepared daily. 115 mg of saponin were added to 10 mL of 0.1 M sodium phosphate buffer, pH 8.0 and mixed to homogeneity via gentle shaking and inversion. 37 mg of proteinase were added and mixed gently to avoid foaming (foaming indicates possible denaturation of protein).
- the lysis solution was filtered with a 32 mm, 0.2 ⁇ m, PES syringe filter. The tube was protected from light to prevent degradation of the enzyme.
- Serratia marcescens ATCC 14756
- Enterobacter cloacae ATCC 13047
- Salmonella choleraesuis ATCC 10708
- Salmonella enteritidis NCTC 4444
- Escherichia coli ATCC 352148
- Klebsiella pneumoniae ATCC 13882
- Pseudomonas aeruginosa 10145
- Staphylococcus aureus ATCC 29213
- Staphylococcus epidermidis 14990
- Streptococcus agalactiae ATCC 13813
- Propionibacterium acnes ATCC 11827
- Bacillus cereus ATCC 10876) were subcultured to non-selective agar media.
- the plates were incubated at 37° C. overnight or at room temperature for 3 days. The following morning they were inoculated to TSB from the freshly subcultured agar media and allowed to incubate at 37° C. for 2 to 4 hours. P. acnes was grown for 1 to 2 days. Broth cultures were diluted 1:10 serially with sterile broth to 1:1,000,000. 10 ⁇ 3 to 10 ⁇ 6 were the four dilutions used for testing.
- Samples were prepared by mixing 1.1 mL, of concentrated platelets and 100 ⁇ L of diluted bacteria in a 3 mL, glass, round-bottom Covaris tube. Two 100 uL aliquots were removed for plating. 1 mL of lysis solution was added to the inoculated platelets. The Covaris tubes were capped and inverted to mix. 200 uL of TCEP were added to platelet solution; and the contents of the Covaris tubes were pipetted vigorously to ensure complete mixing of the sample and to dissociate the gel-like residue that is generated upon addition of TCEP to platelets. The two 100 ⁇ L aliquots (replicates) from the inoculated platelets were plated using a plate spinner and disposable T-spreaders. After incubation the colonies were counted, and the number of CFU/mL added to the platelets was determined.
- the bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes.
- the tubes were loaded into the custom tube holder designed to precisely position the tube.
- Each sample was processed via the Covaris to accelerate the lysis of platelets.
- the samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. For the next 30 seconds, the intensity was set to 2 and the cycles per burst was set to 500. For the final 30 seconds, the cycles per burst was set to 100.
- the lysate was filter-concentrated, hybridized, washed, and mounted as described in the Preferred Embodiments section. It was probed with a TAMRA-labeled universal bacteria PNA probe.
- Gram positive specimens were prepared using 1 ⁇ lysis solution.
- Gram negative samples were prepared using 1 ⁇ 2 X lysis solution with 200 uL TCEP and 10% methanol (v/v) flow wash buffer. The gram negative protocol also worked on gram positives with the same efficacy.
- the slide-bound membranes were examined on the fluorescent microscope using the 60 ⁇ oil objective and the AdvanDx PNA FISH filter cube (XF 53). The goal was to determine which was the most dilute sample with detectable, fluorescent organisms on the membrane in order to establish the lower limit of detection ( FIGS. 3 & 4 ). The results showed that all of the isolates were detectable between 1000 CFU/mL and 10,000 CFU/mL, and S. epidermidis was detectable between 100 CFU/mL and 1,000 CFU/mL by the method of this invention.
- BAL bronchoalveolar lavage
- Samples were prepared by homogenizing large volume or pooled BAL with forceful pipetting and vortexing. 0.5 mL to 1 mL of sample was mixed by inversion and vortexing with 1 mL to 1.5 mL of processing solution in a 3 mL round-bottom, glass Covaris tube.
- the bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes.
- the tubes were loaded into the custom tube holder designed to precisely position the tube.
- the samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. For the next 60 seconds, the intensity was set to 2. For the final 60 seconds, the cycles per burst was set to 200.
- Processing solution was prepared by adding 115 ⁇ L of Triton X 100 to 10 mL of 0.1M sodium phosphate buffer, pH 8 and vortexing to mix thoroughly. 11.25 Units/mL of proteinase were added and vortexed briefly to dissolve. The solution was filtered using a 0.2 ⁇ m, 32 mm, PES syringe filter.
- Samples were prepared by homogenizing with forceful pipetting and vortexing. 1 mL of processing solution, 1 mL of homogenized BAL, and 0.2 mL of TCEP were added to a 3 mL, round bottom, glass Covaris tube. The samples were mixed by inversion and vortexing until uniformly liquid throughout.
- the bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes.
- the tubes were loaded into the custom tube holder designed to fix the X and Y axis.
- the samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. Then the intensity was increased to 2 for 60 seconds. Finally, the cycles per burst were decreased to 200 for 60 seconds.
- the processed BAL was filter-concentrated, hybridized, washed, and mounted as described in the Preferred Embodiments section. It was probed with species specific S. aureus TAMRA-labeled or universal bacteria fluorescein-labeled PNA probe.
- the slide-bound membranes were examined using a fluorescent microscope, a 60 ⁇ oil objective, and the AdvanDx PNA FISH filter cube (XF 53) for fluorescent organisms.
- S. aureus was detected in the BAL with reported S. aureus
- bacilli were detected in the BAL with reported S. marcescens ( FIG. 5 ).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention features methods for selective lysis of endogenous cells in a biological sample. In preferred embodiments, the methods of the invention comprise contacting the biological sample with lysis solution, and subjecting the mixture to ultrasound, thereby selectively lysing the endogenous cells in the biological sample. The invention also features a lysis solution comprising Saponin and Proteinase.
Description
- This application is a continuation application of U.S. application Ser. No. 14/084,026, filed Nov. 19, 2013, which is a continuation application of International Application No. PCT/US2012/038535, filed on May 18, 2012, which claims the benefit of the filing date, under 35 U.S.C. § 119(e), of U.S. Provisional Application No. 61/488,434, filed on May 20, 2011. The entire contents of each of the above-referenced applications are incorporated herein by reference.
- This invention pertains to the field of detection, identification and characterization of microorganisms in complex, cell-containing biological fluids and tissues.
- The ability to detect and characterize low levels of microorganisms in biological samples is valuable for many applications including diagnosing and treating infections in both humans and animals, infectious disease research, detecting food contamination and identifying the causative organisms, monitoring product quality during food processing, monitoring environmental quality and so on.
- Culture is often used to facilitate the detection and characterization of microorganisms in biological samples. The samples are incubated in an atmosphere and at a temperature that is conducive to the growth of microorganisms, possibly with the addition of nutrient media to sample. Under these conditions, the microorganisms will multiply and can reach high concentrations. After growth to a sufficient concentration is achieved, a variety of methods can be used for the detection and characterization of the microorganisms. These methods include staining, fluorescence-in-situ-hybridization (FISH), polymerase-chain-reaction (PCR) and matrix-assisted-laser-desorption-ionization (MALDI) mass spectrometry. The drawback to culture is that it is slow, typically proceeding over many hours. Direct, i.e. non-culture, methods would therefore be preferred in those cases where rapid detection and characterization is important.
- A range of bioanalytical methods rely on the lysis of cells for the release of intracellular components. Such components include organelles such as mitochondria, lysosomes, and endoplasmic reticulum, molecular assemblies such as microtubules and ribosomes and molecules such as proteins, carbohydrates and nucleic acids. Following lysis, the intracellular components can be subjected to analysis by for example electrophoresis, chromatography, mass spectrometry or optical spectroscopy. Likewise, molecular methods such as PCR, microarray analysis and sequencing rely on cell lysis for the release of intracellular DNA and RNA for amplification and other kinds of processing. To meet these needs, various cell lysis methods have been developed. Such methods include osmotic, chemical, mechanical (e.g. grinding with beads), hydrodynamic (e.g. pressure cell) and acoustic (i.e. sonication with ultrasound).
- Ultrasound (acoustic waves beyond the audible range) has been used to lyse cells to release contents for molecular analysis often in conjunction with beads. See Seiter, J. A. and Jay, J. M. 19805. U.S. Pat. No. 5,374,522 (Murphy et al.) describes the use of an ultrasonic bath to disrupt cells such as Mycobacterium tuberculosis in a sample to which beads of glass or other materials in the range of 50 microns to 1 mm have been added. Such disruption released RNA and DNA into solution for hybridization with genetic probes. In U.S. Pat. No. 6,431,476, Taylor et al. teach a method for disrupting cells or viruses in a chamber with an ultrasonic transducer. Chandler et al. (U.S. Pat. No. 6,506,584) teach treating liquid with ultrasound in a flow-through device. The treatment can include cell lysis. U.S. Pat. No. 6,686,195 (Colin et al.) teaches lysing cells in a tube brought into direct contact with a shaped sonotrode. In U.S. Pat. No. 6,881,541 Petersen et al. teach a method for extracting nucleic acid from a sample using ultrasound. In U.S. Pat. No. 6,887,693 McMillan et al. teach a method for lysing components of a fluid sample that have been captured on a solid support. In U.S. Pat. No. 6,893,879, Petersen et al. teach a method for extracting an analyte from a fluid sample. U.S. Pat. No. 6,939,696 (Llorin et al.) teaches disrupting microorganisms in a sonicator at high pH in a lube without beads. In these references, the goal is to disrupt or lyse cells, whether mammalian or bacterial, to release the cell content for analysis. Belgrader et al. (U.S. Pat. No. 7,541,166) describe an apparatus that allows a sample or parts of a sample to be moved into a sonication chamber multiple times, allowing differing sonication levels to be applied to more and less sensitive cells such as epithelial and sperm cells releasing their DNA for analysis at different times.
- In analyzing cell-containing biological samples, it is sometimes advantageous to lyse a subpopulation of the cells present in the sample. For example, when it is desired to perform a differential analysis of the white blood cells in blood using a Coulter counter, it is convenient to lyse the red blood cells while leaving the white blood cells intact. Various lysis solutions have been developed to achieve this result. See for example, U.S. Pat. No. 3,874,852 (Hamill), U.S. Pat. No. 4,185,964 (Lancaster), U.S. Pat. No. 4,521,518 (Carter et al.), U.S. Pat. No. 5,284,940 (Lin et al.), and U.S. Pat. No. 5,958,781 (Wong et al.). It is worth noting that red blood cells lyse fairly readily compared to the white blood cells and selective red blood cell lysis can be accomplished simply with osmotic shock. Agents that selectively lyse bacteria but not mammalian cells have potential utility in combating infections. Oren and Shay studied melittin diastereomers that lyse bacteria but not mammalian cells3. Selective lysis can be useful for biological research. Grifantini and coworkers were able to isolate adherent bacteria co-cultured with epithelial cells for gene expression studies by selectively lysing the epithelial cells with saponin.4
- Direct assays for the detection of microorganisms in biological fluids are often hampered by the presence of endogenous cells in high numbers. In general, such assays can be simplified if a method for selectively removing the endogenous cells were available. Zierdt and his colleagues published a lysis method in 19771. This method uses a mild detergent solution containing an enzyme mixture (Rhozyme prepared from Aspergillus oryzae cultures). In a subsequent paper2, Zierdt refined the solution by substituting the less
toxic detergent Tween 20 for the Triton X-100 used in the original protocol. The Zierdt method is able to process a suitable volume of blood, 1 mL for example, in 1 hour, yielding a clear, red solution that can be filtered through a 0.6 micron track-etch filter 8 mm in diameter in approximately 3 minutes using a pressure differential of 2.5 psi. A key advantage of the Zierdt method is that the product is filterable through filters with pores small enough to retain microorganisms. Following filtration, the filter can be placed on a nutrient plate under suitable conditions, allowing colonies to grow from individual cells. The colonies can then be counted and further analyzed for the identity and antibiotic susceptibility of the organisms. Alternatively, FISH or other fluorescent labeling methods can be applied to the cells and fluorescence microscopy used to directly visualize the cells on the filter. This offers the possibility of rapid detection and identification of microorganisms in a range of complex samples including blood and other clinical specimens. Hence, a method that is able to selectively lyse mammalian cells faster than the Zierdt method would be advantageous. - In addition to the presence of cells, other constituents of biological samples can also hamper the detection of microorganisms. For example, bronchial samples are often highly viscous due to the presence of phlegm and other lung exudates. Urine specimens may contain significant amounts of protein as well as cells and mucus. These materials impede the detection of microorganisms by microscopic methods. Various reagents are used to overcome the obstacles to detection posed by these sample constituents. For example, N-acetyl-L-cysteine (NALC), combined with sodium citrate is a digestant that breaks up mucus in sputum and other bronchial samples. The sodium citrate stabilizes the NALC by binding heavy metal ions that may be present. Such reagents have proven to be useful, but their action is often slow and their effectiveness limited.
- It is therefore an object of the present invention to provide a method for the rapid and efficient lysis of mammalian cells in biological samples while leaving microorganisms (bacteria and fungi) in the sample substantially intact.
- It as a further object of the invention to provide a method for treating viscous, cell and protein containing biological samples to render them liquid and freely flowing without disrupting microorganisms that may be present.
- It is a further object of the invention to provide a method for making highly cellular and/or viscous biological samples filterable through small pore size filters in order to retain and concentrate microorganisms on the filter for further analysis.
- The present invention is directed to achieving the objectives above by means of the surprising discovery that endogenous mammalian cells in a biological sample can be rapidly and effectively lysed while leaving the cells of any microorganisms that may be present substantially intact by mixing the sample with a lysis solution as described herein and subjecting the mixed sample to high-frequency ultrasound of prescribed frequency, power, duty cycle and duration.
- The invention is also directed to liquefying highly viscous biological samples in a rapid manner while preserving substantially all the microorganisms present in viable form, by mixing the sample with an appropriate lysis solution as described herein and subjecting the sample to high-frequency ultrasound of prescribed frequency, power, duty cycle and duration.
- This invention also provides a method for rapidly and effectively capturing microorganisms in intact and viable form from highly cellular and/or viscous biological samples by mixing the sample with an appropriate lysis solution as described herein and subjecting the sample to high-frequency ultrasound of prescribed frequency, power, duty cycle and duration and filtering the treated sample through a filter.
-
FIG. 1 is a graph that shows the filterability of whole blood: lysis solution with and without ultrasonic treatment. -
FIG. 2 shows the results of Fluorescence in situ Hybridization (FISH) experiments for Coagulase Negative Staphylococcus (CNS). The slide-bound membranes were examined using a fluorescent microscope, a 60× oil objective, and the AdvanDx PNA FISH filter cube (XF 53) for fluorescent organisms. CNS was detected in all 4 samples. -
FIG. 3 is a graph that shows peptide nucleic acid (PNA) FISH detection of bacteria in platelet concentrates by CFU/mL. -
FIG. 4 shows the results of FISH experiments for the detection of Bacillus cereus in concentrated platelets. -
FIG. 5 are two panels that show the results of FISH experiments for the detection of Staphylococcus aureus (top) and Serratia inarcescens (bottom) in clinical bronchoalveolar lavage. - Described by the present invention are methods for selective lysis of endogenous cells in a biological sample and method for detecting, identifying, characterizing or quantifying microorganisms in a biological sample, where the sample comprises a mixture of endogenous cells and microorganisms. The present inventors have found that endogenous cells in a biological sample can be rapidly and effectively lysed while leaving the cells of any microorganism that may be present in the sample substantially intact.
- The term “endogenous cells” is meant to refer to those cells that are produced by or originate from or are growing within an organism, tissue or biological sample. For example, in certain preferred embodiments, an endogenous cell may be a mammalian cell.
- The term “biological sample” is meant to refer to cell containing samples. In certain embodiments, a biological sample may be a body fluid, for example, but not limited to, blood or blood fractions, blood culture fluid, respiratory secretions, cerebrospinal fluid, urine, stool, wound exudates and naso-pharyngeal fluid or mucus. In other embodiments, the biological sample may be platelets, platelet concentrate or a mammalian cell culture. In still other embodiments, the biological sample may be food or edible products.
- In preferred embodiments, the phrase “substantially intact” is meant to mean that the microorganisms are viable (i.e. they are capable of growing) or that their cells appear to be intact when imaged under a microscope in either stained or unstained form. In related preferred embodiments, the phrase “substantially intact” is meant to refer to at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more of the microorganisms in the sample are recovered.
- In certain exemplary embodiments, the method comprises mixing the biological sample with a lysis solution, and subjecting the mixture to ultrasound at a controlled temperature, thereby selectively lysing the endogenous cells in the biological sample.
- Selective Lysis
- As mentioned above, a method for selectively lysing mammalian cells while leaving microorganisms intact was developed by Zierdt and his colleagues. The method, published in 1977, uses a mild detergent solution containing an enzyme mixture (Rhozyme prepared from Aspergillus oryzae cultures). 30 mL of blood mixed with conventional blood culture medium (brain heart infusion broth, sodium polyanethol sulfate, p-aminobenzoic acid, 3% CO2) is mixed with 20 mL lysis solution (0.1% Triton X-100 in 0.01M NaHCO3—Na2CO3 buffer with 3% of stock Rhozyme 41 solution) and incubated for 30 minutes at 37° C. Samples lysed in this manner are capable of being filtered through 0.45 micron pore size filters. Zierdt subsequently refined the solution by substituting the less
toxic detergent Tween 20 for the Triton X-100 used in the original protocol. Later, Zierdt studied a variety of detergents useful in blood lysis for their efficacy in lysing blood and their toxicity to bacteria as components of blood culture media.6 In addition to Triton X-100 andTween 20, Brij 96 and digitonin performed well. - However, the Zierdt method has the drawbacks of a lengthy incubation, a large (10:1) dilution of the sample, and the presence of residual blood cell nuclei in the lysed sample.
- Lysis Solutions
- Lysis solutions can be useful in assays for microorganisms for the purpose of lysing endogenous cells as well as liquefying and clarifying mucus and phlegm containing samples. In addition to the Rhozyme-based lysis solution described above, various compositions of lysis solutions have been developed often containing detergents, enzymes, salts and buffering agents.
- Saponins, produced by certain plants, are ambipathic glycoside detergent compounds that bind cholesterol. Saponins have been found to be particularly effective for the selective lysis of mammalian cells in microbial cell assays.
- Gordon Dorn in U.S. Pat. No. 4,164,449 teaches a method of concentrating microbial cells from blood by lysing the blood with saponin, centrifuging the lysed blood and removing the residual blood components from the microorganisms that are now in the pellet. The saponin is preferably treated to remove toxic components according the method taught in U.S. Pat. No. 3,883,425 also by Dorn which uses ultrafiltration to remove low-molecular weight components considered to be toxic to microorganisms.
- In U.S. Pat. No. 5,501,960, Dorn teaches the use of sodium polyanethol sulfonate in combination with purified saponin to improve the recovery of microorganisms from specimens containing blood components.
- The Dorn method requires mixing the blood with the saponin-containing lysis solution followed by 30 minutes of centrifugation. After centrifugation, the majority of the supernatant is removed and discarded. The microorganism-containing pellet is resuspended and distributed onto growth media for culture. After culture, colonies can be counted and analyzed. While quantitative, this method requires overnight culture and is somewhat labor intensive.
- In U.S. Pat. No. 5,043,267, Richards teaches the use of saponin to lyse blood containing phagocytosed pathogens to release degraded pathogen while leaving unphagocytosed pathogens intact. Antigens from the degraded pathogens are detected with an immunoassay while the intact pathogens arc cultured for confirmation of the assay result. Richards extends the Dorn method and allows detection of certain microbial antigens in one hour. The antigens are cell membrane constituents (lipoteichoic acid and peptidoglycan) which are not very specific. The ability of this method to identify microorganisms is therefore limited.
- According to the invention, lysis solutions can comprise detergents or detergents combined with proteinase. In particularly preferred embodiments, the lysis solution comprises a detergent and a proteinase. Detergents useful in the invention include, but are not limited to, saponin, nonionic surfactants such as Triton X-100 and polysorbate surfactants such as
Tween 20. In preferred embodiments, detergent concentrations can range from 0.1 to 10%. Proteinases useful in the invention include proteinases derived from Aspergillus (e.g. Aspergillus melleus) which have broad enzyme activity and those with more specific activity like Streptokinase which speeds the dissolution of fibrin clots. Commercially available Proteinase from Aspergillus melleus in the range of 8 Units/mL to 160 Units/mL has been shown to work. Other enzymes can be combined with proteinase to promote the breakdown of certain biomolecules. Cholesterol esterase, lipase and DNase are examples of enzymes that can be used in combination with proteinase. Reducing agents such as TCEP can be helpful for liquefying mucoid samples by reducing the disulfide bonds in mucin strands. Chaotropic agents such as guanidinium chloride can also aid in the dissolution of mucin gels by disrupting non-covalent bonds. Hypotonic salt solutions can also promote lysis. - According to certain preferred exemplary embodiments, the present inventors have found that a combination of saponin with proteinase from Aspergillus melleus in a phosphate buffer is particularly effective.
- Accordingly, the present invention features a lysis solution comprising a detergent and a proteinase, preferably a lysis solution comprising Saponin and Proteinase. In certain embodiments, the lysis solution further comprises a Sodium Phosphate buffer,
pH 8. - The lysis solution preferably comprises 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%, 1.16%, 1.17%, 1.18%, 1.19%, 1.2%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%, 1.29%, 1.30%, 1.31,%, 1.32%, 1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.40%, 1.41%, 1.42%, 1.43%,1.44%, 1.45%, 1.46%, 1.47%, 1.48%, 1.49%, 1.50%, 1.55%, 1.60%, 1.65%, 1.70%, 1.72%, 1.75%, 1.80%, 1.82%, 1.85%, 1.90%, 1.92%, 1.95%, 2.0%, 2.2%, 2.5%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, or 10.0% Saponin. Preferably, the lysis solution comprises 1.15% Saponin.
- The lysis solution preferably comprises 5.0, 5.25, 5.5, 6.0, 6.25, 6.5, 7.0, 7.25, 7.5, 8.0, 8.25, 8.5, 9.0, 9.25, 9.5, 10.0, 10.25, 10.5, 11.0, 11.25, 11.5, 12.0, 12.25, 12.5, 13.0, 13.25, 13.5, 14.0, 14.25, 14.5, 15.0, 15.25, 15.5, 16.0, 16.25, 16.5, 17.0, 17.25, 17.5, 18.0, 18.25, 18.5, 19.0, 19.25, 19.5, 20.0, 20.25, 20.5, 21.0, 21.25, 21.5, 22.0, 22.25, 22.5, 23.0, 23.25, 23.5, 24.0, 24.25, 24.5, 25.0, 25.25, 25.5, 26.0, 26.25, 26.5, 27.0, 27.25, 27.5, 28.0, 28.25, 28.5, 29.0, 29.25, 29.5, 30.0, 31.25, 31.5, 32.0, 32.25, 32.5, 33.0, 33.25, 33.5, 34.0, 34.25, 34.5, 35.0, 35.25, 35.5, 36.0, 36.25, 36.5, 37.0, 37.25 or 37.5 Units Proteinase. In preferred embodiments, the lysis solution comprises 11.25 Units Proteinase.
- Buffer concentrations from 0.01M to 0.1M have been tested. Tris and DNase running buffer have been used in place of sodium phosphate buffer. Accordingly, in further related embodiments, other buffers known to one skilled in the art can be used. It is therefore likely that other buffers can be substituted.
- In certain preferred embodiments, the lysis solution comprises
-
- 0.1M Sodium Phosphate buffer,
pH 8; - 1.15% Saponin; and
- 11.25 Units/mL Proteinase.
- 0.1M Sodium Phosphate buffer,
- In further preferred embodiments, the Saponin is from Quillaja bark. Preferably, the Proteinase is from Aspergillus melleus.
- In other exemplary embodiments, the lysis solution comprises
-
- 0.1M Sodium Phosphate buffer,
pH 8 - 1.15% Saponin from Quillaja bark (Sigma 54521-25G)
- 11.25 Units/mL Proteinase from Aspergillus melleus, Type XXIII (Sigma P4032-25G)
- 0.1M Sodium Phosphate buffer,
- Sonics
- As mentioned above, ultrasound has been used to lyse cells to release the intracellular contents for molecular analysis. Beads of glass or other materials are often added to the sample to increase the mechanical action of the ultrasound. Transducers of various shapes have been used. In the prior work the outcome has been the comprehensive lysis of all the cells in the sample. By contrast, in the methods of the present invention the selective lysis of particular cell populations is achieved.
- Two rather different types of ultrasound generating equipment are available. They are distinguished by the operating frequency. One type operates in the frequency range of 20 kHz (just above the range of human hearing) to about 80 kHz. The other type operates in the frequency range of 500 kHz to 1.5 MHz or higher and is often called megasonics. In the former, the wavelength of the sound waves ranges from about 80 mm to about 20 mm; while in the latter, the wavelength ranges from about 3 mm to about 1 mm. The shorter wavelengths produced in the megasonic range allow better localization of the sonic energy to the biological sample that may have a volume of approximately 1 cm3. Moreover, bubbles produced by cavitation will generally be smaller at higher frequencies since the shorter cycles give them less time to grow before they collapse in the compressive phase of the cycle. As used herein, the term “high frequency ultrasound” is meant to refer to ultrasound in the megasonic range.
- Some embodiments described below employ the Covaris S2 high frequency ultrasound system. In that system, a concave transducer is used to focus the acoustic energy on the sample. The transducer operates in a water bath in which the sample tube is immersed. The acoustic energy is coupled to the sample by the water. The system operates at approximately 500 KHz in a pulsed mode. The number of cycles per burst, the duty cycle, time duration and the intensity are settable on the instrument.
- Covaris Settings:
- The following settings have been found to provide optimum results with the Covaris S2.
- Heat water bath to 37° C.
- Degas water bath for 30 min prior to use per manufacturer's instruction.
-
Mix 1 mL of blood with 1 mL of lysis solution in a 3 mL round-bottom glass tube. - Treat sample for 100 seconds at 10% duty cycle, 1 intensity, 1000 cycles/burst.
- Treat sample for 60 seconds at 10% duty cycle, 2 intensity, 1000 cycles/burst.
- Treat sample for 60 seconds at 10% duty cycle, 2 intensity, 200 cycles/burst.
- Lower intensity (intensity setting 1) can be used in the last two steps if the duration is increased.
- Other embodiments use a non-focused, high-frequency ultrasound system manufactured by ProSys, Inc. In this system, a planar transducer emits a directed beam of ultrasound. The diameter of the beam is governed by the size of transducer. The system operates at approximately 1 MHz. The duty cycle, time duration and the intensity are settable on the instrument. Sonic energy from the transducer can be coupled into the biological sample by water, a gel, or an elastomer.
- ProSys Settings:
- The following settings have been found to provide optimum results with the ProSys.
- 100 ms Pulse
- 50% Duty Cycle
- 45 Watts
- 5 minute duration
- The present inventors have found that when used as described above, these systems are effective in achieving the selective lysis of mammalian cells while leaving microorganisms intact and viable.
- Systems operating at lower frequencies (20 to 40 kHz) are available from other suppliers such as Branson Ultrasonics. These do not focus the acoustic energy with a focusing transducer but can concentrate the energy with a transducer probe having a narrow tip. Our experience with these systems has shown them to be much less effective in lysing blood cells than the high frequency systems.
- Filtration
- It can be advantageous to filter lysed samples through filters having pores sufficiently small to retain microorganisms in the sample. As previously mentioned, the retained microorganisms can be supplied with nutrients and grown into colonies on the membrane for counting and further analysis or they can be visualized on the filter by fluorescence microscopy following treatment with fluorescent probes or antibodies. 0.6 micron and 0.45 micron filters are commonly used to capture bacteria and fungi from liquid samples. 0.45 micron and 0.2 micron filters are commonly used for filter sterilization of water and media. Blood and other cell-containing biological samples are not directly filterable with these filters because the filters are rapidly clogged by these highly cellular liquids. Filterability is a good measure of the effectiveness of a lysis procedure.
- Various types of filters can be used. Membrane filters made of nylon, polycarbonate, polyester and aluminum oxide have been used. Track-etch membranes of polycarbonate or polyester are useful if it is desired to image microorganisms in a sample after the lysis procedure. These membranes feature smooth, flat surfaces with well-controlled cylindrical pores. Anopore (aluminum oxide) filters are also flat with well-controlled pores and thus useful for imaging. Pore sizes from 0.2 to 1 micron are effective for retention of bacteria and yeast with 0.45 to 0.8 micron being most useful. Larger pore sizes (up to 4 microns) can be used if only yeast (fungi) are of interest.
- Detection and Identification of Microorganisms
- Various assays for the detection and identification of microorganisms have been developed. Three general classes of assays are in common use. The first class encompasses culture-based methods whereby any microorganisms present in the biological sample are allowed to grow perhaps with the admixture of nutrient media into the sample. The growth of the microorganism(s) can be detected in various ways, such as by changes in the turbidity or the pH of the sample or by the evolution of CO2 driven by the metabolic activity of the microorganisms during their growth. Microorganisms can be identified on the basis of which of a range of biochemical nutrient sources they are able to utilize for growth. Likewise, their resistance to various antibiotics can be assessed by characterizing their ability to grow in the presence of different concentrations of the antibiotics of interest. Culture-based methods are widely used for both identification and characterization of microorganisms. The primary disadvantage of these methods is the length of time (8 to 24 hours) required to get results.
- The second class of assays involve the use of stains, binding agents or probes to confer a detectable color or label to the cells of any microorganisms that may be present. Microscopic examination is generally used to visualize the colored or labeled cells.
- The Gram stain is an example of a stain that is commonly used in microbiology. It involves the use of crystal violet and iodine to stain fixed bacterial cells. Gram positive bacteria can be distinguished from Gram negative bacteria by their ability to retain the purple color of the crystal violet stain after washing with alcohol or acetone. Gram negative bacteria lose the purple color during the wash and are stained pink by the counter-stain, usually safranin or basic fuchsin, applied after the wash.
- Antibodies are examples of binding agents. Antibodies that recognize and bind to bacterial cell-surface molecules have been developed. Such antibodies can be chemically modified to incorporate fluorescent tags. They can be utilized in assays such as direct fluorescence assays (DFA) in which one or more fluorescently tagged antibodies are mixed with the biological sample to be tested and incubated to allow antibody binding. Following a wash step, the sample is examined with a fluorescent microscope to detect cells to which the fluorescent antibodies have bound. Other examples of binding agents include aptamers, peptides, lectins and phages.
- Probes are molecules that incorporate nucleobases. They can bind to DNA or RNA by hydrogen bonding of the nucleobases in the probe to complementary nucleobases in the DNA or RNA in a process called base pairing. Probes can be made up of DNA, PNA (peptide nucleic acid), LNA (locked nucleic acid), and related molecules and combinations thereof. The number and sequence of the nucleobases in a probe determine what target sequence the probe will bind to according to the rules of base pairing, as well as the strength and specificity of the binding. The strength of the binding under various conditions of salt concentration and pH depends on type(s) of the component molecules (DNA, PNA, LNA and others) that make up a probe. Probes can incorporate fluorescent labels that make them detectable by fluorescence imaging.
- Many different fluorescent labels (fluorophores) have been developed for use in biological assays. There are labels with excitation and emission wavelengths ranging from the ultraviolet to the near-infrared regions of the electromagnetic spectrum. Labels further differ in the width of the excitation and emission bands, the Stokes shift, and the fluorescence lifetime. Representative fluorescent labels include fluorescein, tetramethyl rhodamine, Texas Red, and Cy5.
- Fluorescence-in-situ-hybridization (FISH) is an assay utilizing fluorescently labeled probes. In one type of FISH assay, probes directed at ribosomal RNA (rRNA) are used. The sequence of rRNA varies from species to species. This allows FISH assays to be made species-specific through the proper design of the probe sequence. Agents that help to preserve RNA directly such as TCEP and the cationic, quaternary ammonium salts, tetra- and hexa-decyltrimethylammonium bromide, like those found in RNAprotect Bacteria Reagent (Qiagen 76506) or indirectly by maintaining the bacterial cell wall (e.g. MgSO4) can be beneficial to these assays. PNA FISH assays are commercially available for diagnostic use in hospital clinical microbiology laboratories for the identification of microorganisms in suspected blood stream infections. In these assays, the probes comprise fluorescently labeled PNA molecules.
- The advantage of this second class of assays is that they result in intact cells that can be microscopically examined This allows the size, shape and clustering characteristics of the cells to be assessed along with the staining behavior. PNA FISH is particularly advantageous because of its generality, high specificity and easily visualized fluorescence.
- The third class of assays for the detection and identification of microorganisms encompasses those that involve the use of molecular methods, including amplification techniques such as PCR. In contrast to the first two classes of assays in which the cells to be detected remain intact, in these assays the target is microbial DNA, RNA or proteins that have been released by the lysis or rupture of the cells. In the case of PCR, the product(s) of the amplification can be detected by sequencing, through the use of microarrays, by the use of intercalating dyes or with probes carrying a detectable label such as one or more fluorophores or nanoparticles. Amplification-based methods suffer from certain drawbacks including false negatives due to inhibitors present in many biological samples, and false positives caused by remnant DNA from microorganisms killed by host defense mechanisms.
- Selective ultrasonic lysis of whole blood, concentrated platelets, respiratory secretions, urine, or blood culture for the purpose of microbial detection is carried out by treating the sample with a buffered solution comprised of saponin or Tween-20 and proteinase in a ratio ranging from 1:1 to 1:4; lysing the mixture with focused or planar high-frequency ultrasonic waves; and concentrating the lysed sample via filtration or centrifugation. Detection can then be accomplished by the following additional steps: rinsing the concentrate; probing the rinsed concentrate with fluorescently labeled PNA probes and hybridizing the probes to specific rRNA targets; stringent washing to remove unbound and non-specifically hybridized probe; and analyzing the sample to detect fluorescent microorganisms. These are the preferred protocols.
- Reagent Preparation
- The lysis solutions were optimized individually for each sample type. Saponin was chosen for the lysis of whole blood and platelets for its superior ability to lyse blood cell membranes while leaving bacterial cells intact. Tween-20 was used in place of saponin for respiratory secretions because the sample was easier to filter after treatment with Tween-20 while still preserving the microorganisms.
- Whole Blood and Blood Culture Formulation
-
- 1) Add 115 mg saponin from Quillaja bark purified to remove low molecular weight contaminants (Sigma S4521) to 10 mL 0.1M sodium phosphate buffer,
pH 8. - 2) Vortex briefly to dissolve.
- 3) Add 112.5 Units of Proteinase from Aspergillus melleus Type XXIII (Sigma S4032) to the solution.
- 4) Vortex briefly to dissolve.
- 5) Filter solution with a 32 mm, polyethersulfone (PES) 0.2 um syringe filter.
- 1) Add 115 mg saponin from Quillaja bark purified to remove low molecular weight contaminants (Sigma S4521) to 10 mL 0.1M sodium phosphate buffer,
- Concentrated Platelet Formulation
-
- 1) Add 58 mg saponin from Quillaja bark purified to remove low molecular weight contaminants (Sigma S4521) to 10 mL 0.1M sodium phosphate buffer,
pH 8. - 2) Vortex briefly to dissolve.
- 3) Add 56.25 Units of proteinase from Aspergillus melleus Type XXIII (Sigma S4032) to the solution.
- 4) Vortex briefly to dissolve.
- 5) Filter solution with a 32 mm PES 0.2 um syringe filter.
- 1) Add 58 mg saponin from Quillaja bark purified to remove low molecular weight contaminants (Sigma S4521) to 10 mL 0.1M sodium phosphate buffer,
- Possible perturbations: The concentration of saponin and/or proteinase may be increased to promote filterability or decreased to improve recovery. Additional agents to promote degradation of fibrin clots and filterability such as Streptokinase may be added.
- Respiratory Secretions Formulation
-
- 1) Add 115 μL of Tween-20 to 10 mL 0.1M sodium phosphate buffer,
pH 8. - 2) Vortex well to mix completely.
- 3) Add 112.5 Units of proteinase from Aspergillus melleus Type XXIII (Sigma S4032).
- 4) Vortex briefly to dissolve.
- 5) Filter solution with a 32 mm PES 0.2 um syringe filter.
- 1) Add 115 μL of Tween-20 to 10 mL 0.1M sodium phosphate buffer,
- Urine Formulation
-
- 1) Add 25 μL of Tween-20 to 50 mL of 1× Phosphate Buffered Saline (Sigma P7059).
- 2) Filter solution with a 32 mm PES 0.2 um syringe filter.
- Possible perturbations: Proteinase may be added to this formulation to increase filterability.
- Sample Preparation
-
- 1) Add 1 mL of lysis solution to a 3 mL round bottom glass tube (Covaris 520067).
- 2) Add 1 mL of sample: whole blood anti-coagulated with sodium heparin, concentrated platelets anti-coagulated with acid-citrate-dextrose (ACD), or respiratory secretions without preservative.
- 3) Cap tube (SUN-SRi 200596) and invert to mix several times.
- Possible perturbations: 1) 200 μL of Bond Breaker TCEP Solution (Thermo Scientific 77720) may be added to the preparation to protect RNA and/or to improve filterability of respiratory secretions. 2) For very thick, mucoid respiratory secretions or for blood culture with 105 CFU/mL or more less sample may be added to the preparation and the difference in volume may be replaced with additional lysis solution, water, or buffer. 3) Anti-coagulants other than those listed above may be used for whole blood and concentrated platelets.
- Ultrasonic Lysis
- The sample was treated with acoustic energy to promote mixing, selectively lyse human cells over bacteria and yeast, and break apart sample matrix for improved filtration. This has been done with focused acoustic energy in the Covaris S2 and non-focused acoustic energy with the ProSys.
- Covaris Method
-
- 1) Heat water bath to 37° C. by setting chiller to 37.7° C.
- 2) Degas water bath for 30 min prior to use per manufacturer's instruction.
- 3) Place 3 mL glass tube into tube holder (custom-built tube holder with fixed positioning of the tube in the vertical and horizontal axes).
- 4) Treat sample for 100 seconds at 10% duty cycle, 1 intensity, 1000 cycles/burst
- 5) Treat sample for 60 seconds at 10% duty cycle, 2 intensity, 1000 cycles/burst
- 6) Treat sample for 60 seconds at 10% duty cycle, 2 intensity, 200 cycles/burst
- Possible perturbations: 1) Reduce treatment time in step 5 and 6 to 30 seconds and cycles/burst to 500 in step 5 and to 100 in step 6 to improve recovery in platelets. 2) Treat urine with 3 cycles of step 6 only. 3) Treat blood culture with 1 cycle of step 6 only.
- Concentration, Hybridization, and Detection
- The lysate was concentrated on an aluminum and SiO2 coated polycarbonate track etched membrane (PCTE) filter bonded to a plastic slide with a ring press and supported by a stainless steel fit. The slide was held in a custom-built, heated slide holder with a vacuum manifold. The filtration area was 52 mm2.
- Concentration Method
-
- 1) Filter entire lysate using a vacuum equivalent 5 to 15 inches of Hg.
- 2) Rinse filter and holder 3 times with 830 μL each of 1× PBS while vacuuming.
- 3) Turn off and purge vacuum.
- Possible perturbations: 1) The lysate may be rinsed with a 1% solution of dextran sulfate, RNAprotect, and/or 400 mM MgCl2 in 1× PBS to improve hybridization and detection. 2) The lysate may be concentrated using centrifugation rather than filtration. 3) Less than the entire volume of lysate may be filtered for samples from which only high colony count organisms are relevant like urine.
- Hybridization and Wash Method
-
- 1) Filter PNA FISH Flow Hybridization Buffer immediately prior to use with a 13 mm, 0.2 μm. polytetrafluorethylene (PTFE) syringe filter.
- 2) Add 400 μL of filtered or PNA FISH Flow Hybridization Buffer containing 100 nM to 500 nM or 50 nM probe for bacteria or yeast respectively to the holder.
- 3) Cover the holder to prevent evaporation.
- 4) Heat the retentate and hybridization buffer in the holder for 30 minutes at 55° C.
- 5) Vacuum away hybridization buffer.
- 6) Turn off and purge vacuum.
- 7) Add 500 μL of PNA FISH Flow Wash Buffer to the holder.
- 8) Cover holder to prevent evaporation.
- 9) Heat the retentate and wash buffer in the holder for 10 minutes at 55° C.
- 10) Vacuum away wash buffer.
- 11) Turn off and purge vacuum.
- 12) Repeat steps 6-10.
- Possible perturbations: 1) Add 40 ul of Bond Breaker TCEP Solution to the holder with the hybridization buffer to protect RNA and improve hybridization and detection. 2) Add 10% methanol to the wash buffer to preserve Gram negative cells during wash step. 3) Use Tween-20 in the wash buffer rather than Triton-X to preserve Streptococcus pneumoniae. 4) Add 1% solution of dextran sulfate, RNAprotect, and/or 400 mM MgCl2 to the wash buffer improve hybridization and detection.
- Detection
-
- 1) Remove slide from the holder and allow to air dry.
- 2) Add 1 drop of mounting media (20% (v/v) 1M Tris-HCl pH 7.6, 80% (v/v) glycerol and 2% (w/v) DABCO) and a 15 mm, round, glass coverslip (Ted Pella, Inc. 26024).
- 3) View and image filter immediately after adding mounting media on a fluorescent microscope or automated scanner.
- Possible perturbations: The concentrated, hybridized lysate may be fixed to and viewed, imaged, and/or scanned on a solid surface rather than a filter.
- Mass Spectrometry Analysis
- Following lysis, mass spectrometry (MS) can be used for detection, identification, characterization or quantification of microorganisms in a sample.
- In an embodiment, the detection, identification, characterization or quantification is done by a mass spectrometer, which may be one of the following: matrix-assisted-laser-desorption-ionization (MALDI) mass spectrometry (e.g. MALDI-TOF MS), Tandem MS, ESI-TOF, ESI-iontrap, LC-MS, GC-MS, ion mobility MS, laser desorption ionization mass spectrometry (LDI-MS) and quadrupole-MS. Other mass spectrometry devices and methods now existing or which may be developed are also within the scope of the present invention.
- Mass spectrometry is a sensitive and accurate technique for separating and identifying molecules. Generally, mass spectrometers have two main components, an ion source for the production of ions and a mass-selective analyzer for measuring the mass-to-charge ratio of ions, which is and converted into a measurement of mass for these ions. Several ionization methods are known in the art and described herein.
- Different mass spectrometry methods, for example, quadrupole mass spectrometry, ion trap mass spectrometry, time-of-flight mass spectrometry, gas chromatography mass spectrometry and tandem mass spectrometry, can utilize various combinations of ion sources and mass analyzers which allows for flexibility in designing customized detection protocols. In addition, mass spectrometers can be programmed to transmit all ions from the ion source into the mass spectrometer either sequentially or at the same time. Furthermore, a mass spectrometer can be programmed to select ions of a particular mass for transmission into the mass spectrometer while blocking other ions.
- Mass spectrometers can resolve ions with small mass differences and measure the mass of ions with a high degree of accuracy. The high degree of resolution and mass accuracy achieved using mass spectrometry methods allows the use of large sets of tagged probes because the resulting reporter tags can be distinguished from each other. The ability to use large sets of tagged probes is an advantage when designing multiplex experiments.
- Another advantage of using mass spectrometry is based on the high sensitivity of this type of mass analysis. Mass spectrometers achieve high sensitivity by utilizing a large portion of the ions that are formed by the ion source and efficiently transmitting these ions through the mass analyzer to the detector. Because of this high level of sensitivity, even limited amounts of sample can be measured using mass spectrometry.
- Mass spectrometry methods are well known in the art (see Burlingame et al. Anal. Chem. 70:647R-716R (1998); Kinter and Sherman, Protein Sequencing and Identification Using Tandem Mass Spectrometry Wiley-Interscience, New York (2000)).
- In recent years, MALDI-TOF mass spectrometry has emerged as a powerful tool for the identification of bacteria and other microorganisms. The advantages of this approach include relatively straightforward sample preparation and rapid analysis. Intact bacterial cells from, for example, a colony can be mixed with MALDI matrix and applied directly to the MALDI sample plate. Pattern recognition applied to the complex spectra that are obtained allows identification of bacteria, often to the strain level (see Lay. Mass Spectrometry Reviews 20: 172-194 (2001)).
- Mass spectrometry and MALDI-TOF in particular is well suited for the analysis of microorganisms obtained using the methods of the invention.
- The examples below demonstrate the methods for clinical samples such as blood, platelet concentrates and bronchoalveolar lavage. The method will have utility for many other types of samples in which the detection of microorganisms at low levels is of value. These include biological samples such as tissue, stool, lavage fluids, needle aspirates and saliva. Another category includes foods such as milk, meats, cheese and vegetables.
- Whole, sodium heparin anti-coagulated blood was mixed 1:1 or 1:10 with a lysis solution based on Zierdt's refined lysis solution (Zierdt, J. Clin. Microbiol., 1982) which contained Rhozyme 41 (Rohm and Hass, Philadelphia, Pa.), a crude proteinase mixture extracted from Aspergillus oryzae and Tween-20 in sodium phosphate buffer. Rhozyme 41 was no longer available; proteinase from Aspergillus melleus was substituted. The mixtures of blood and lysis solution were subjected to one hour incubation at 37° C., focused ultrasonic waves in the Covaris, or no treatment. Then they were tested for filterability and examined microscopically to assess the number of residual cells.
- Two lysis solutions were made—one with and one without detergent. The lysis solutions were made by adding 350 μL of Tween-20 to 49.65 mL of 0.01 M sodium phosphate buffer and mixing thoroughly. Then, if required, 250 mg of proteinase were added and briefly vortexed to dissolve. Lysis solutions were filtered with a 0.2 μm, 32 mm, PES syringe filter.
- Samples were prepared by adding 0.5 mL of whole blood and 0.5 mL of lysis solution (1:1) to a 2 mL, round-bottom, snap-cap, plastic microcentrifuge tube (Eppendorf 022363352) or 0.1 mL of blood and 0.9 mL of lysis solution (1:10). The samples were capped and inverted to mix. The samples remained at these concentrations during the incubation at 37° C. or treatment with the Covaris. The 1:1 sample was diluted 1:5 before being examined microscopically or tested for filterability in order to obtain the same blood to fluid ratio as the 1:10 samples.
- Samples were heated in a 37° C. water bath for one hour in accordance with Zierdt's lysis procedure (Zierdt, J. Clin. Microbiol., 1982). Other samples were treated with the Covaris S2 instead of heat. The Covaris bath was filled with deionized water, degassed for 30 minutes, and chilled to 7° C. to promote better sound transmission according to the manufacturer's recommendations. The Covaris bath was not chilled for all of the testing in order to promote proteinase activity. When the bath was not chilled it reached 25° C. The Covaris samples were treated for 60 consecutive seconds at an intensity of 3, 10% duty cycle, and 200 cycles per burst. Control samples were mixed with lysis solution and tested immediately after mixing.
- All samples were examined for residual cells using bright field microscopy and a 20× objective. Slides were made by pipetting 15 μL of thoroughly mixed sample (1:10) onto a glass slide and adding a 22×22 mm coverslip. An average number of cells was taken over multiple fields of view.
- All samples were tested for filterability as a measure of how well the cells had been lysed. The barrel from a 3 mL syringe was fitted with a 13 mm, 0.45 μm, nylon syringe filter. The outlet of the syringe filter was attached to a vacuum pulling at 5″ Hg. The filter was primed with 0.5 mL of 1× PBS. Another 1 mL of 1× PBS was filtered and timed to obtain a normalization value for each filter. Finally 1 mL of sample mixed with lysis solution and either treated with heat or sonic energy or untreated was filtered and timed.
-
TABLE 1 Filterability and Microscopic Appearance of Whole Blood Following Various Lytic Treatments Blood:Lysis Microscopy Filtration Solution Lysis Solution and Treatment (cells/20X field) (sec) 1:10 Detergent 25 ∞ Detergent & proteinase 75 27 Detergent & proteinase for 1 hr @ 1 23 37° C. (Zierdt method) Detergent with Covaris @ 7° C. 0 15 Detergent & proteinase with Covaris 0 14 @ 25° C. 1:1 Detergent & proteinase for 1 hr @ Not tested in this experiment; this 37° C. does not filter Detergent with Covaris @ 7° C. 12-18 61 Detergent & proteinase with Covaris 12-18 15 @ 25° C. - Results showed that treatment with ultrasonic energy produced a lysate that was more filterable and contained less cellular debris than the Zierdt method (Table 1). Although not tested during these experiments, other work showed the Zierdt method produced a product that was not filterable if used in a 1:1 mixture with whole blood. They also demonstrated that the composition of the lysis fluid has secondary contributions to filterability. However, it was unclear whether the significant gain in filterability for the 1:1 sample with detergent and proteinase over the sample with detergent only was due to the proteinase or the warmer Covaris bath. Further experiments were conducted at the same temperature. The results showed adding proteinase to the ultrasonic lysis increases filterability and may also reduce the number of residual blood cells even though the sonic treatment only lasted 60 seconds and it was at room temperature (Table 2). This indicates that the acoustic energy may have been speeding up enzymatic reactions as well as shearing cells.
-
TABLE 2 Filterability and Microscopic Appearance of Whole Blood Treated with Proteinase and Ultrasonic Energy Blood:Lysis Lysis Microscopy Filtration Solution Solution and Treatment (cells/20X field) (sec) 1:1 Detergent with Covaris 10 38 @ 20° C. Detergent & proteinase 2-3 20 with Covaris @ 20° C. - International patent application WO 2009/015484 A1 (Peytavi et al.) demonstrates the concentration of microbial cells from whole blood using high concentrations of heat-treated saponin and centrifugation. 10% heat-treated saponin in the lysis solution with proteinase and Covaris treatment did not improve filterability (Table 3).
-
TABLE 3 Filterability of Whole Blood Treated with High Concentration Saponin and Ultrasonic Energy Saponin Concentration in Lysis Solution Filtration (sec) 10%, heat-treated 69 1.4%, untreated 51 0.7%, untreated 56 - Nine different microorganisms were inoculated into whole, sodium heparin treated blood. The blood was mixed with lysis solution and plated before and after ultrasonic lysis. The plates were incubated overnight and colonies were counted in the morning to determine percent yield after Covaris treatment in blood and lysis solution.
- Candida albicans, Candida krusei, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis were subcultured to non-selective agar media. The plates were incubated at 37° C. overnight. The following morning they were inoculated to broth media from the freshly subcultured agar media and allowed to incubate at 37° C. for 2.5 hours. Bacteria and yeast were diluted serially with 1× PBS with 0.05% Tween-20 to 1:1,000 or 1:10,000.
- Lysis solution was made by adding 350 μL of Tween-20 to 49.65 mL of 0.01M sodium phosphate buffer and mixing thoroughly. Then 250 mg of proteinase were added and briefly vortexed to dissolve. The lysis solution was filtered with a 0.2 μm, 32 mm, PES syringe filter.
- Samples were prepared by adding 0.5 mL of whole blood, 0.5 mL of lysis solution, and 10 to 40 μL. of the diluted microorganisms to a 2 mL, round-bottom, snap-cap, plastic microcentrifuge tube. The samples were capped and inverted to mix. 100 μL of the blood mixture were plated using a plate spinner and a disposable, sterile T-spreader before and after treatment with the Covaris. The plates were incubated overnight at 37° C. overnight. Colonies were counted and recorded the following morning to determine percent yield (Table 4). This experiment was performed three times.
- Samples were treated with the Covaris S2. The Covaris bath was filled with deionized water and degassed for 30 minutes. The water bath was maintained at 20° C. The Covaris samples were treated for 60 consecutive seconds at an intensity of 2, 10% duty cycle, and 200 cycles per burst.
-
TABLE 4 Recovery from Whole Blood after Ultrasonic Lysis Yield Average Standard Organism Experiment 1 Experiment 2 Experiment 3 Yield Deviation C. albicans 300% 263% 243% 268% 29 C. krusei 63% 217% 129% 136% 77 E. faecium 92% 134% 267% 164% 91 E. faecalis 150% 123% 165% 146% 21 E. coli 88% 61% 63% 70% 15 K. pneumoniae 93% 41% 50% 61% 28 P. aeruginosa 41% 56% 48% 48% 8 S. aureus 171% 164% 143% 159% 15 S. epidermidis 93% 70% 192% 118% 65 - The results showed some yields were greater than 100%. In this experiment, the microorganisms were quantitated by the number of colonies formed after overnight growth. Cells in a cluster or chain form single colonies and thus represent single colony forming units (cfu). If disrupted, such clusters can form multiple colonies. We have observed that immediately following treatment with the Covaris, organisms that normally occur in clusters are generally seen to be present in single cell form.
- The results also indicated some loss of viability. The impact was greatest on Gram negative rods.
- Staphylococcus aureus (SA) that had been diluted serially was inoculated into sterile, fresh, whole, sodium heparin treated blood and incubated to allow for phagocytosis. The blood was then split into two samples and subjected to either selective lysis or turned into a mock blood culture. The portion that underwent selective lysis was filtered. The filter was placed on an agar plate and incubated overnight. Colonies were counted in the morning. The portion that was made into a mock blood culture was incubated two days and checked for growth using Gram stain and subculture to an agar plate. The results of both methods were compared to the number of CFU initially inoculated into the blood and to each other.
- SA (ATCC 29213) was subcultured to trypticase soy agar with 5% sheep blood and incubated at 37° C. overnight. The following morning it was inoculated into trypticase soy broth and incubated at 37° C. at 180 rpm for 2 hours. The broth was then diluted serially 1:10 with 1× phosphate buffered saline with 0.05% Tween-20 to 1×10−9. 100 μl of the 10−5 and 10−6 dilutions and 1 mL of the 10−7, 10−8, and 10−9 dilutions were filtered with the Microfil V Filtration Device (Millipore MVHAWG124) that had been pre-wetted with 1× phosphate buffered saline. The device contains a 47 mm, mixed cellulose ester filter with 0.45 μm pores and a printed grid for counting colonies. The filter was removed from the device, placed on trypticase soy agar, and incubated overnight at 30° C. The filters were examined for growth the following morning, and colonies were counted. These counts were used to estimate how many CFU were added to the aliquots of blood.
- The lysis solution was prepared by adding 140 mg of saponin to 10 mL of 0.1M sodium phosphate buffer,
pH 8 and vortexing to dissolve. Then 51 mg of proteinase were added and vortexed briefly to dissolve. The solution was filtered with a 0.2 μL, 32 mm, PES syringe filter. - Five 2.5 mL aliquots of blood were inoculated with 50 μL each of the last five SA dilutions, 10−5 to 10−9, and incubated for 1 hour at 37° C. to allow for phagocytosis. The samples were then mixed and split into separate 1 mL aliquots. The excess 0.55 mL from each sample was discarded. Each 1 mL aliquot was either mixed with 1 mL of lysis solution or 3 mL of BacT/ALERT SA blood culture media (Biomérieux 259789).
- The mock blood cultures were incubated for 2 days at 37° C. and 180 rpm. They were Gram stained and subcultured semi-quantitatively to trypticase soy agar each morning to monitor for growth. The agar subcultures were incubated overnight at 37° C. and examined for growth the following morning.
- The bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes. The aliquots that were mixed with lysis solution were loaded into the custom tube holder designed to fix the X and Y axis. The samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst.
- Then the intensity was increased to 2 for 60 seconds. Finally, the cycles per burst were decreased to 200 for 60 seconds.
- The lysed samples were filtered on Microfil V filtration devices that had been pre-wetted with 1× phosphate buffered saline. The filters were rinsed with more 1× phosphate buffered saline. The filters were removed from the device, placed on trypticase soy agar, and incubated overnight at 30° C. The filters were examined for growth the following morning, and colonies were counted.
-
TABLE 5 Comparison of Selective Lysis of Whole Blood and Blood Culture Number of Approx. CFU Colonies from Added to Selectively Lysed Growth or No Each Split Whole Blood on Growth of Blood Sample Day 1 Culture 64.6 159 Growth Day 16.8 37 Growth Day 10.56 0 No Growth Day 2 0.04 0 No Growth Day 2 0 0 No Growth Day 2 - The data demonstrate that selective lysis of whole blood for the detection of SA was as sensitive as blood culture. Selective lysis, however, has the advantage that isolated colonies were available for analysis after overnight incubation; whereas, the blood culture would require another overnight incubation before overnight colonies were available (Table 5).
- Four leftover clinical samples of ethylenediaminetetraacetic acid (EDTA) anti-coagulated whole blood from suspected catheter-related blood stream infections (CR-BSI), reported clinically as 106 cfu/mL Coagulase Negative Staphylococcus (CNS), were received frozen. They were defrosted, mixed with lysis solution, treated with focused ultrasonic energy, and filter concentrated. The retentate was probed using the PNA Flow FISH method on the membrane and examined using fluorescent microscopy.
- Lysis solution was prepared by adding 115 mg of saponin to 10 mL of 0.1M sodium phosphate buffer,
pH 8 and vortcxing to dissolve. 11.25 Units/mL of proteinase were added and vortexed briefly to dissolve. The solution was filtered using a 0.2 μm, 32 mm, PES syringe filter. - Samples were prepared by adding 1 mL of lysis solution and 1 mL of defrosted blood to a 3 mL, round bottom, glass Covaris tube. The samples were mixed by inversion.
- The bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes. The tubes were loaded into the custom tube holder designed to fix the X and Y axis. The samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. Then the intensity was increased to 2 for 60 seconds. Finally, the cycles per burst were decreased to 200 for 60 seconds.
- The lysed samples were filter-concentrated, hybridized, washed, and mounted as described in the Preferred Embodiments section. The retentate was probed with a three probe mixture containing a S. aureus specific, fluorescein-labeled probe, a CNS specific, TAMRA-labeled probe, and universal bacteria, Cy5-labeled probe.
- The slide-bound membranes were examined using a fluorescent microscope, a 60× oil objective, and the Advanllx PNA FISH filter cube (XF 53) for fluorescent organisms. CNS was detected in all 4 samples (
FIG. 2 ). - Whole blood anti-coagulated with sodium heparin was inoculated with E. coli, mixed with lysis solution and subjected to non-focused ultrasound from the ProSys megasonic bowl instrument. Samples were plated before and after treatment with the ProSys to determine recovery and tested for filterability.
- An adjustable tube holder for the ProSys megasonic bowl was devised by attaching a clip to a manual positioning stage of the kind used for optics prototyping. The tool clip was kept level to keep the sample parallel to the transducer surface. The positioning stage allowed the height of the tube to be precisely adjusted in order to maximize the amount of activity within the sample while it was being treated with the ProSys. The ProSys bowl was filled with deionized water. The transducer was used to heat the water in the bowl until it reached 35° C.
- Lysis solution was made by adding 115 mg of saponin to 10 mL of 0.1 M sodium phosphate buffer and vortexing to dissolve. Then 112.5 units of proteinase were added and briefly vortexed to dissolve. The lysis solution was filtered with a 0.2 μm, 32 mm, PES syringe filter.
- Samples were prepared by adding 1 mL of whole blood and 1 mL of lysis solution to a 15 mL Falcon tube. The tubes were sealed with a cyclic-olefin polymer (COP), pressure-sensitive adhesive tape (Adhesives Research, ARseal 90404) and mixed by inversion.
- The tubes were clipped topside down to the tube holder and lowered into the bath until fully submerged. They were treated with the ProSys for 5 consecutive minutes with 45 watts, 100 ms pulse, and 50% duty cycle. The temperature was maintained in the bowl between 36° C. and 38° C. by removing warm water and replacing it with icy, deionized water. The lysate was removed from the tube holder and tested for filterability as described in Example 1. Identical samples were subjected to focused sonic lysis by the Covaris in parallel with the ProSys samples for comparison (Table 6). This experiment was performed four times.
-
TABLE 6 Comparison of ProSys and Covaris Whole Blood Lysate Filterability Experiment Ultrasonic System Filtration (sec) 1 ProSys 55 1 ProSys 60 1 ProSys 46 1 ProSys 62 1 Covaris 57 2 ProSys 63 2 ProSys 63 2 ProSys 70 2 Covaris 56 3 ProSys 40 3 ProSys 44 3 ProSys 43 3 ProSys 50 3 Covaris 52 4 ProSys 46 4 ProSys 47 4 ProSys 46 4 ProSys 60 4 Covaris 55 - The results showed that the lysis produced by the non-focused acoustic energy from the ProSys compared favorably to the focused ultrasonic energy from the Covaris. The results also indicate that the lysis can be done reliably and reproducibly. Recovery assays were done with E. coli to test whether lysis caused by the ProSys was selective for blood cells.
- Escherichia coli was subcultured to a trypticase soy agar (TSA) plate and incubated at 37° C. overnight. The following morning it was inoculated to trypticase soy broth (TSB) media from the freshly subcultured plate and allowed to incubate at 37° C. for 2 hours. 350 μL of sterile broth were added to 600 μL of broth culture. The E. coli were further diluted serially with 1× PBS with 0.05% Tween-20 to 1:10,000. 20 μL of diluted culture were added to samples prepared as described above.
- 100 μL of the samples were plated before and after treatment with the ProSys (as described above) using a plate spinner and a disposable, sterile T-spreader. The plates were incubated overnight at 37° C. Colonies were counted and recorded the following morning to determine percent yield. Identical samples were subjected to focused sonic lysis by the Covaris in parallel with the ProSys samples for comparison (Table 7).
-
TABLE 7 E. coli Recovery from Whole Blood after Lysis with the ProSys Ultrasonic CFU CFU System Pre-Lysis Post-Lysis Yield ProSys 29 11 38% ProSys 25 17 68% ProSys 32 12 38 % ProSys 20 13 65% Covaris 28 15 54% - The recovery results for lysis with the ProSys compared favorably to the Covaris.
- Platelets from one unit of blood (450 mL) were separated and concentrated in approximately 30 mL of plasma by centrifugation. 1 mL aliquots of platelet concentrate were inoculated with bacteria, mixed 1:1 with lysis solution, and selectively lysed using the Covaris S2. The lysates were filtered, and the retentates were probed with fluorescently labeled universal bacteria PNA probe. The filters were examined on a fluorescent microscope for the presence of bacteria. The platelets were plated pre- and post-lysis to determine the detection limits of this invention.
- The platelets were stored on a rotational shaker (Manufacturer: VWR, Model: S-500 Orbital Shaker) at ambient temperature. The speed of oscillation was set between 3 and 4 such that an overall speed of 70 rotations per minute was achieved. Platelets were extracted from the bag in a laminar flow hood using aseptic technique.
- Lysis solution was prepared daily. 115 mg of saponin were added to 10 mL of 0.1 M sodium phosphate buffer, pH 8.0 and mixed to homogeneity via gentle shaking and inversion. 37 mg of proteinase were added and mixed gently to avoid foaming (foaming indicates possible denaturation of protein). The lysis solution was filtered with a 32 mm, 0.2 μm, PES syringe filter. The tube was protected from light to prevent degradation of the enzyme.
- Serratia marcescens (ATCC 14756), Enterobacter cloacae (ATCC 13047), Salmonella choleraesuis (ATCC 10708), Salmonella enteritidis (NCTC 4444), Escherichia coli (ATCC 35218), Klebsiella pneumoniae (ATCC 13882), Pseudomonas aeruginosa (10145), Staphylococcus aureus (ATCC 29213), Staphylococcus epidermidis (14990), Streptococcus agalactiae (ATCC 13813), Propionibacterium acnes (ATCC 11827), Bacillus cereus (ATCC 10876) were subcultured to non-selective agar media. The plates were incubated at 37° C. overnight or at room temperature for 3 days. The following morning they were inoculated to TSB from the freshly subcultured agar media and allowed to incubate at 37° C. for 2 to 4 hours. P. acnes was grown for 1 to 2 days. Broth cultures were diluted 1:10 serially with sterile broth to 1:1,000,000. 10−3 to 10−6 were the four dilutions used for testing.
- Samples were prepared by mixing 1.1 mL, of concentrated platelets and 100 μL of diluted bacteria in a 3 mL, glass, round-bottom Covaris tube. Two 100 uL aliquots were removed for plating. 1 mL of lysis solution was added to the inoculated platelets. The Covaris tubes were capped and inverted to mix. 200 uL of TCEP were added to platelet solution; and the contents of the Covaris tubes were pipetted vigorously to ensure complete mixing of the sample and to dissociate the gel-like residue that is generated upon addition of TCEP to platelets. The two 100 μL aliquots (replicates) from the inoculated platelets were plated using a plate spinner and disposable T-spreaders. After incubation the colonies were counted, and the number of CFU/mL added to the platelets was determined.
- The bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes. The tubes were loaded into the custom tube holder designed to precisely position the tube. Each sample was processed via the Covaris to accelerate the lysis of platelets. The samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. For the next 30 seconds, the intensity was set to 2 and the cycles per burst was set to 500. For the final 30 seconds, the cycles per burst was set to 100.
- The lysate was filter-concentrated, hybridized, washed, and mounted as described in the Preferred Embodiments section. It was probed with a TAMRA-labeled universal bacteria PNA probe. Gram positive specimens were prepared using 1× lysis solution. Gram negative samples were prepared using ½ X lysis solution with 200 uL TCEP and 10% methanol (v/v) flow wash buffer. The gram negative protocol also worked on gram positives with the same efficacy.
- The slide-bound membranes were examined on the fluorescent microscope using the 60× oil objective and the AdvanDx PNA FISH filter cube (XF 53). The goal was to determine which was the most dilute sample with detectable, fluorescent organisms on the membrane in order to establish the lower limit of detection (
FIGS. 3 & 4 ). The results showed that all of the isolates were detectable between 1000 CFU/mL and 10,000 CFU/mL, and S. epidermidis was detectable between 100 CFU/mL and 1,000 CFU/mL by the method of this invention. - Large volume or pooled leftover clinical samples of bronchoalveolar lavage (BAL) were obtained from a hospital laboratory. They were mixed with different processing solutions, treated with the Covaris to break apart mucous, debris, and cells, and tested for filterability.
- Samples were prepared by homogenizing large volume or pooled BAL with forceful pipetting and vortexing. 0.5 mL to 1 mL of sample was mixed by inversion and vortexing with 1 mL to 1.5 mL of processing solution in a 3 mL round-bottom, glass Covaris tube.
- The bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes. The tubes were loaded into the custom tube holder designed to precisely position the tube. The samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. For the next 60 seconds, the intensity was set to 2. For the final 60 seconds, the cycles per burst was set to 200.
- All samples were tested for filterability as a measure of how well the BAL had been processed. The barrel from a 3 mL syringe was fitted with a 13 mm, 0.45 μm, nylon syringe filter. The outlet of the syringe filter was attached to a vacuum pulling at 5″ Hg. The filter was primed with 0.5 mL of 1× PBS. Another 1 mL of 1× PBS was filtered and timed to obtain a normalization value for each filter. Finally 2 mL of sample mixed with processing solution either treated with sonic energy or untreated was filtered and timed (Table 8).
-
TABLE 8 Development of BAL Processing Solution % Filtered Filtra Before tion- Processing Solution Clogging (sec) 0.5 mL BAL + 1.5 mL solution (pooled BAL #8-11) Sodium Phosphate Buffer 10 n/a Sodium Phosphate Buffer + Covaris 33 n/a Saponin + Covaris 70 n/a Saponin + DNase + Covaris 100 161 DNase + Covaris 20 n/a Triton X-100 + Covaris 100 36 Guanidinium Cl + Covaris 50 n/a Sputolysin + Covaris 25 n/a NaLC + Sodium Citrate + Covaris 40 n/a TCEP + Covaris 40 n/a 1 mL BAL + 1 mL solution (pooled BAL #8-11) Triton X-100 + Covaris 45 n/a 1 mL BAL + 1 mL solution (large volume BAL # 12) Sodium Phosphate Buffer 15 n/a Sodium Phosphate Buffer + Covaris 30 n/a Triton + Protease + Covaris 100 26 Triton X-100 + Covaris 50 n/a Triton + Protease + DNase + Covaris 100 40 Triton + DNase + Covaris 100 63 Guanidinium + Triton + Covaris 100 33 NaLC + Sodium Citrate + Triton + Covaris 100 76 Triton + Protease + DNase + Guanidinium + Covaris 100 29 Triton + Protease + DNase + NaLC + Covaris 100 35 Repeat Triton + Protease + Covaris 100 28 Repeat Triton + Protease + DNase + Covaris 100 39 1 mL BAL + 1 mL solution (large volume BAL # 14) Sodium Phosphate Buffer 5 n/a Sodium Phosphate Buffer + Covaris 10 n/a Mucolexx + Covaris 10 n/a Triton + Protease + NaLC + Covaris 55 n/a Triton + Protease + NALC + NaCitrate + Covaris 45 n/a Triton + Protease + Guanidinium + Covaris 100 140 Triton + Protease + Covaris 30 n/a Triton + Protease + TCEP + Covaris 100 35 Triton + Protease + NALC + DNase + Covaris 30 n/a Triton + Protease + NALC + DNase in Running 55 n/a Buffer + Covaris Triton + Protease + TCEP + DNase in Running 100 69 Buffer + Covaris 1 mL BAL + 1 mL solution (large volume BAL # 17) Sodium Phosphate Buffer 10 n/a Sodium Phosphate Buffer + Covaris 18 n/a Triton + Protease + Covaris 45 n/a Triton + Protease + TCEP + DNase in Running 100 43 Buffer + Covaris Triton + Protease + TCEP + Covaris 100 26 - Results showed that a processing solution with
Triton X 100, proteinase, and TCEP followed by treatment with the Covaris produced the most reliably filterable sample. Others additives such as DNase may or may not improve the efficacy of the processing solution. However, there was some concern about the harmful effects thatTriton X 100 may have on bacteria so some alternatives toTriton X 100 were also tested (Table 9). -
TABLE 9 Triton X 100 Alternatives for BAL Processing Solution% Filtered Filtration Processing Solution Before Clogging (sec) 0.5 mL BAL + 1.5 mL solution (pooled BAL #64-66) NaCl + Protease + TCEP + Covaris 100 32 DexS04 + Protease + TCEP + Covaris 100 42 SDS + Protease + TCEP + Covaris 100 24 Triton + Protease + TCEP + Covaris 100 30 Saponin + Protease + TCEP + Covaris 100 28 Tween-20 + Protease + TCEP + Covaris 100 29 1 mL BAL + 1 mL solution (pooled BAL #67-68) Saponin + Protease + TCEP + Covaris 18 n/a Saponin + Protease + TCEP + Covaris 26 n/a Saponin + Protease + TCEP + High [DNase] + Covaris 14 n/a Saponin + Protease + TCEP + Low [DNase] + Covaris 16 n/a Saponin + Protease + TCEP + High [Gelsolin] + Covaris 22 n/a Saponin + Protease + TCEP + Low [Gelsolin] + Covaris 26 n/a 0.5 mL BAL + 1.5 mL solution (pooled BAL #67-68) Saponin + Protease + TCEP + Covaris 82 n/a Tween-20 + Protease + TCEP + Covaris 100 35 Saponin + Tween-20 + Protease + TCEP + Covaris 100 73 - Results showed that Tween-20 along with proteinase, and TCEP followed by ultrasonic treatment was a promising alternative to
Triton X 100 in the processing solution for BAL. - Leftover positive clinical BAL samples (BAL #18 and #43 clinical reports: “few Staphylococcus aureus and Usual throat organism” and “≧10K cfu/mL Serratia marcescens” respectively) were mixed with processing solution, treated with focused ultrasonic energy, and filter concentrated. The retentate was probed using the PNA Flow FISH method on the membrane and examined using fluorescent microscopy.
- Processing solution was prepared by adding 115 μL of
Triton X 100 to 10 mL of 0.1M sodium phosphate buffer,pH 8 and vortexing to mix thoroughly. 11.25 Units/mL of proteinase were added and vortexed briefly to dissolve. The solution was filtered using a 0.2 μm, 32 mm, PES syringe filter. - Samples were prepared by homogenizing with forceful pipetting and vortexing. 1 mL of processing solution, 1 mL of homogenized BAL, and 0.2 mL of TCEP were added to a 3 mL, round bottom, glass Covaris tube. The samples were mixed by inversion and vortexing until uniformly liquid throughout.
- The bath on the Covaris was filled with deionized water, heated to 37° C., and degassed for 30 minutes. The tubes were loaded into the custom tube holder designed to fix the X and Y axis. The samples were warmed and mixed for 100 seconds at an intensity of 1, 10% duty cycle, and 1000 cycles per burst. Then the intensity was increased to 2 for 60 seconds. Finally, the cycles per burst were decreased to 200 for 60 seconds.
- The processed BAL was filter-concentrated, hybridized, washed, and mounted as described in the Preferred Embodiments section. It was probed with species specific S. aureus TAMRA-labeled or universal bacteria fluorescein-labeled PNA probe.
- The slide-bound membranes were examined using a fluorescent microscope, a 60× oil objective, and the AdvanDx PNA FISH filter cube (XF 53) for fluorescent organisms. S. aureus was detected in the BAL with reported S. aureus, and bacilli were detected in the BAL with reported S. marcescens (
FIG. 5 ). - All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
-
-
- 1. Zierdt, C. H., Kagan, R. L. and J. D. MacLowry. 1977. Development of a Lysis-Filtration Blood Culture Technique. J. Clin. Microbiol. 5:46-50.
- 2. Zierdt, C. H. 1982. Blood-Lysing Solution Nontoxic to Pathogenic Bacteria. J. Clin. Microbiol. 15:172-174.
- 3. Oren, Z. and Shai, Y. 1997. Selective Lysis of Bacteria but Not Mammalian Cells by Diastereomers of Melittin: Structure-Function Study. Biochemistry. 36(7):1826-1835
- 4. Grifantini R, Bartolini E, Muzzi A, Draghi M, Frigimelica E, Berger J, Ratti G, Petracca R, Galli G, Agnusdei M, Giuliani M M, Santini L, Brunelli B, Tettelin H, Rappuoli R, Randazzo F, Grandi G. 2002. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nature Biotechnol 20: 914-21.
- 5. Seiter, J. A. and Jay, J. M. 1980. Application of Polyacrylamide Gel Electrophoresis to the Characterization and Identification of Arthrobacter Species. Int. J. Syst. Bacteriol., 30:460-465
- 6. Zierdt, C. H. 1986. Simplified Lysed-Blood Culture Technique. J. Clin. Microbiol. 23:452-455.
Claims (34)
1-65. (canceled)
66. A lysis solution for selective lysis of endogenous cells in a biological sample comprising:
a detergent; and
a proteinase.
67. The lysis solution of claim 66 , further comprising a Sodium Phosphate buffer, pH 8.
68. The lysis solution of claim 67 , wherein the Sodium Phosphate buffer is at pH 8.
69. The lysis solution of claim 66 , wherein the detergent is selected from the group consisting of Saponin, nonionic surfactant and polysorbate surfactant.
70. The lysis solution of claim 69 , wherein the nonionic surfactant comprises Triton X-100.
71. The lysis solution of claim 69 , wherein the polysorbate surfactant comprises Tween 20.
72. The lysis solution of claim 66 , wherein the detergent is Saponin.
73. The lysis solution of claim 72 , wherein the Saponin is from Quillaja bark.
74. The lysis solution of claim 66 , wherein the proteinase is derived from Aspergillus.
75. The lysis solution of claim 74 , wherein the proteinase is derived from Aspergillus melleus.
76. The lysis solution of claim 72 , comprising 0.1%-10% Saponin.
77. The lysis solution of claim 76 , comprising 1.15% Saponin.
78. The lysis solution of claim 66 , comprising 5.0-37.5 Units Proteinase.
79. The lysis solution of claim 78 , comprising 11.25 Units Proteinase.
80. The lysis solution of claim 67 , comprising 0.01-0.1M Sodium Phosphate buffer, pH 8.
81. The lysis solution of claim 80 , comprising 0.1M Sodium Phosphate buffer, pH 8.
82. The lysis solution of claim 66 , further comprises an enzyme selected from the group consisting of cholesterol esterase, lipase and DNase.
83. The lysis solution of claim 66 , further comprises a reducing agent.
84. The lysis solution of claim 83 , wherein the reducing agent comprises TCEP.
85. The lysis solution of claim 66 , further comprises a chaotropic agent.
86. The lysis solution of claim 85 , wherein the chaotropic agent comprises guanidinium chloride.
87. The lysis solution of claim 66 , further comprising a hypotonic salt solution.
88. The lysis solution of claim 66 , wherein the biological sample is a body fluid.
89. The lysis solution of claim 88 , wherein the body fluid is selected from the group consisting of: blood or blood fractions, respiratory secretions, cerebrospinal fluid, urine, stool, wound exudates (pus), and naso-pharyngeal fluid/mucus.
90. The lysis solution of claim 66 , where the biological sample is selected from the group consisting of: platelets, platelet concentrate and a mammalian cell culture.
91. A lysis solution for increasing filterability of bronchoalveolar lavage comprising:
Triton X-100 or Tween 20;
Protease; and
TCEP.
92. The lysis solution of claim 91 , further comprises Sodium Phosphate Buffer, pH 8.
93. A method for selective lysis of endogenous cells in a bronchoalveolar lavage sample and increasing filterability of the sample comprising:
contacting the bronchoalveolar lavage sample with the lysis solution of claim 26; and
subjecting the mixture of the bronchoalveolar lavage sample and lysis solution to high-frequency ultrasound;
thereby selectively lysing the endogenous cells in the bronchoalveolar lavage sample.
94. The method of claim 93 , wherein the endogenous cells are mammalian cells.
95. The method of claim 93 , wherein the bronchoalveolar lavage sample comprises microorganisms.
96. The method of claim 95 , wherein the microorganisms are selected from the group consisting of: bacteria, yeast and fungi.
97. The method of claim 93 , further comprising filtering or centrifuging the lysed sample; and
detecting, identifying, characterizing or quantifying microorganisms in the biological sample;
thereby detecting, identifying, characterizing or quantifying microorganisms in the biological sample.
98. The method of claim 97 , wherein the detecting, identifying, characterizing or quantifying is carried out using peptide nucleic acid (PNA) fluorescent in situ hybridization (FISH).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/666,042 US20180057856A1 (en) | 2011-05-20 | 2017-08-01 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161488434P | 2011-05-20 | 2011-05-20 | |
PCT/US2012/038535 WO2012162133A1 (en) | 2011-05-20 | 2012-05-18 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
US14/084,026 US9719128B2 (en) | 2011-05-20 | 2013-11-19 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
US15/666,042 US20180057856A1 (en) | 2011-05-20 | 2017-08-01 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/084,026 Continuation US9719128B2 (en) | 2011-05-20 | 2013-11-19 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180057856A1 true US20180057856A1 (en) | 2018-03-01 |
Family
ID=47217646
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/084,026 Expired - Fee Related US9719128B2 (en) | 2011-05-20 | 2013-11-19 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
US15/666,042 Abandoned US20180057856A1 (en) | 2011-05-20 | 2017-08-01 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/084,026 Expired - Fee Related US9719128B2 (en) | 2011-05-20 | 2013-11-19 | Selective ultrasonic lysis of blood and other biological fluids and tissues |
Country Status (4)
Country | Link |
---|---|
US (2) | US9719128B2 (en) |
EP (1) | EP2710127A4 (en) |
CA (1) | CA2839794A1 (en) |
WO (1) | WO2012162133A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022159641A1 (en) * | 2021-01-23 | 2022-07-28 | Academia Sinica | Method for treating hepatocellular carcinoma |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687239B2 (en) | 2003-07-12 | 2010-03-30 | Accelrs Technology Corporation | Sensitive and rapid determination of antimicrobial susceptibility |
US20120077206A1 (en) | 2003-07-12 | 2012-03-29 | Accelr8 Technology Corporation | Rapid Microbial Detection and Antimicrobial Susceptibility Testing |
US9434937B2 (en) | 2011-03-07 | 2016-09-06 | Accelerate Diagnostics, Inc. | Rapid cell purification systems |
US10254204B2 (en) | 2011-03-07 | 2019-04-09 | Accelerate Diagnostics, Inc. | Membrane-assisted purification |
US9677109B2 (en) | 2013-03-15 | 2017-06-13 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
US20170072228A1 (en) | 2014-03-31 | 2017-03-16 | University Of Washington | Methods and systems for selectively disrupting tissue with high intensity focused ultrasound |
WO2015189390A1 (en) | 2014-06-13 | 2015-12-17 | Q-Linea Ab | Method for detecting and characterising a microorganism |
AU2016243656A1 (en) | 2015-03-30 | 2017-11-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
US10253355B2 (en) | 2015-03-30 | 2019-04-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
GB201507026D0 (en) | 2015-04-24 | 2015-06-10 | Linea Ab Q | Medical sample transportation container |
EP3153589A1 (en) * | 2015-10-09 | 2017-04-12 | Université de Fribourg | Kit and methods for the rapid detection of the absence or presence of resistance to beta-lactam compounds in urine samples |
GB2554767A (en) | 2016-04-21 | 2018-04-11 | Q Linea Ab | Detecting and characterising a microorganism |
GB201617713D0 (en) | 2016-10-19 | 2016-11-30 | Q-Linea Ab | Method for recovering microbial cells |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2019116034A1 (en) * | 2017-12-12 | 2019-06-20 | Cell Therapy Catapult Limited | Microbial enrichment method |
GB201801022D0 (en) * | 2018-01-22 | 2018-03-07 | Q Linea Ab | Single dye concentration determination |
KR20210134681A (en) * | 2019-02-28 | 2021-11-10 | 데이 제로 다이아그노스틱스, 인크. | Improved Methods for Preparing Clinical Samples for Nucleic Acid Amplification |
CN110044670B (en) * | 2019-03-27 | 2022-08-09 | 广州金域司法鉴定技术有限公司 | Kit, method and method for extracting narcotics in hair |
WO2020202113A1 (en) * | 2019-04-05 | 2020-10-08 | Thermo Fisher Scientific Oy | Mass spectrometric methods and compositions for identifying microbes from blood by reducing confounding proteins |
CN110628762A (en) * | 2019-10-14 | 2019-12-31 | 杭州同创越诚基因科技有限公司 | Nucleic acid extraction method based on nano magnetic beads and application |
JP7361228B2 (en) | 2020-04-28 | 2023-10-13 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | Acoustophoretic lysis devices and methods |
WO2024005867A1 (en) * | 2022-06-30 | 2024-01-04 | Siemens Healthcare Diagnostics Inc. | Acoustophoretic analyzation devices and methods |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693972A (en) * | 1984-01-16 | 1987-09-15 | Becton, Dickinson And Company | Composition and method for rapid detection of microorganisms in clinical samples |
US20080138809A1 (en) * | 2006-06-14 | 2008-06-12 | Ravi Kapur | Methods for the Diagnosis of Fetal Abnormalities |
WO2009015484A1 (en) * | 2007-08-02 | 2009-02-05 | Universite Laval | Concentration and enrichment of microbial cells and microbial nucleic acids from bodily fluids |
WO2010003690A1 (en) * | 2008-07-10 | 2010-01-14 | Carpegen Gmbh | Device for analysing a chemical or biological sample |
WO2010124001A1 (en) * | 2009-04-21 | 2010-10-28 | Advandx, Inc. | Multiplex analysis of cells, particles, and other analytes |
US20120164648A1 (en) * | 2010-12-28 | 2012-06-28 | Bexmart | Integrated Versatile and Systems Preparation of Specimens |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT386838B (en) * | 1986-11-17 | 1988-10-25 | Agrocon Agrar Consulting | MEANS FOR ACTIVATING FERMENTATIVE PROCESSES AND METHOD FOR ACCELERATING THE FERMENTATIVE DEGRADATION OF NATURAL SUBSTANCES |
US5284940A (en) | 1990-11-14 | 1994-02-08 | Hri Research, Inc. | Preparation for nucleic acid samples |
JP3529786B2 (en) | 1994-07-14 | 2004-05-24 | アボット・ラボラトリーズ | Cyanide-free assay method and reagents for hemoglobin and leukocytes in whole blood |
AU2005305347A1 (en) * | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
GB0508981D0 (en) * | 2005-05-03 | 2005-06-08 | Acolyte Biomedica Ltd | Distinguishing cells in a sample |
JP5319549B2 (en) | 2006-12-29 | 2013-10-16 | アボット・ラボラトリーズ | Non-denaturing cell lysis reagent for in-solution capture immunoassay |
US20100203521A1 (en) * | 2007-04-02 | 2010-08-12 | Boston Medical Center Corporation | Method for bacterial lysis |
WO2009063198A2 (en) * | 2007-11-14 | 2009-05-22 | Prokyma Technologies Limited | Extraction and purification of biological cells using ultrasound |
US10415075B2 (en) * | 2008-10-31 | 2019-09-17 | Biomerieux, Inc. | Method for separation, characterization and/or identification of microorganisms using mass spectrometry |
US10167494B2 (en) | 2008-10-31 | 2019-01-01 | Biomerieux, Inc. | Method for detection, characterization and/or identification of microorganisms in a sealed container |
CN102272601B (en) * | 2008-10-31 | 2014-09-17 | 生物梅里埃公司 | Methods for separation and characterization of microorganisms using identifier agents |
WO2013023198A2 (en) * | 2011-08-11 | 2013-02-14 | Zybac, Llc | Rapid and sensitive detection of bacteria in blood products, urine, and other fluids |
-
2012
- 2012-05-18 EP EP12790065.2A patent/EP2710127A4/en not_active Withdrawn
- 2012-05-18 CA CA2839794A patent/CA2839794A1/en not_active Abandoned
- 2012-05-18 WO PCT/US2012/038535 patent/WO2012162133A1/en active Application Filing
-
2013
- 2013-11-19 US US14/084,026 patent/US9719128B2/en not_active Expired - Fee Related
-
2017
- 2017-08-01 US US15/666,042 patent/US20180057856A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693972A (en) * | 1984-01-16 | 1987-09-15 | Becton, Dickinson And Company | Composition and method for rapid detection of microorganisms in clinical samples |
US20080138809A1 (en) * | 2006-06-14 | 2008-06-12 | Ravi Kapur | Methods for the Diagnosis of Fetal Abnormalities |
WO2009015484A1 (en) * | 2007-08-02 | 2009-02-05 | Universite Laval | Concentration and enrichment of microbial cells and microbial nucleic acids from bodily fluids |
WO2010003690A1 (en) * | 2008-07-10 | 2010-01-14 | Carpegen Gmbh | Device for analysing a chemical or biological sample |
WO2010124001A1 (en) * | 2009-04-21 | 2010-10-28 | Advandx, Inc. | Multiplex analysis of cells, particles, and other analytes |
US20120164648A1 (en) * | 2010-12-28 | 2012-06-28 | Bexmart | Integrated Versatile and Systems Preparation of Specimens |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022159641A1 (en) * | 2021-01-23 | 2022-07-28 | Academia Sinica | Method for treating hepatocellular carcinoma |
Also Published As
Publication number | Publication date |
---|---|
US9719128B2 (en) | 2017-08-01 |
WO2012162133A1 (en) | 2012-11-29 |
EP2710127A1 (en) | 2014-03-26 |
US20140186832A1 (en) | 2014-07-03 |
EP2710127A4 (en) | 2014-12-03 |
CA2839794A1 (en) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180057856A1 (en) | Selective ultrasonic lysis of blood and other biological fluids and tissues | |
US11072813B2 (en) | Selective lysis of cells | |
WO2022040453A1 (en) | Blood cell lysing agent for isolating bacteria from blood culture | |
JP6533468B2 (en) | Specific isolation method of nucleic acid of interest | |
AU2016200341B2 (en) | Methods for the Isolation, Accumulation Characterization and/or Identification of Microorganisms Using a Filtration and Sample Transfer Device | |
JP2017093464A (en) | Selective lysis of cells by ionic surfactants | |
US20060134729A1 (en) | Process for the universal detection of microorganisms and reaction environment permitting the implementation of the process | |
CN102471798A (en) | Mass spectrometric diagnosis of septicemia | |
JP2012511318A (en) | Automated system for lysis of microorganisms present in samples intended for analysis and extraction and purification of nucleic acids of these microorganisms | |
US20100305312A1 (en) | Method For The Extraction And Purification Of Nucleic Acids On A Membrane | |
US20160264925A1 (en) | Reagents for Lysis of Bacterial Cells | |
US20200355588A1 (en) | Method of pretreating blood sample | |
JP5599013B2 (en) | Extraction method of microbial nucleic acid from blood sample | |
WO2020085420A1 (en) | Cell collection method | |
JP2008125457A (en) | Method for detection of microorganism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANDX, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUCHS, MARTIN;MELTZER, MICHELLE;REEL/FRAME:044163/0021 Effective date: 20120725 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |